CURRICULUM VITAE
OREGON HEALTH AND SCIENCE UNIVERSITY

Name: Eric Roeland, MD, FASCO, FAAHPM **Date Prepared:** January 30, 2026

Phonetic Spelling: "ERR-ik" "r-OH-L-ahn-d" **Pronouns:** he / him / his / él

I. PRESENT POSITION AND ADDRESS

Associate Professor
Oregon Health and Science University
Department of Medicine
Division of Hematology/Oncology
Division of Oncological Sciences
Medical Oncology and Palliative Care
Knight Cancer Institute
Director, Symptom Science Research

Oregon Health and Science University
Knight Cancer Institute
Division of Hematology and Medical Oncology
3181 SW Sam Jackson Park Road, OC14HO
Portland, OR 97239

E-mail: roeland@ohsu.edu

II. EDUCATION

Undergraduate and Graduate

09/96 - 06/00	BA	Spanish Language and Literature	Northwestern University
06/01 - 06/05	MD	Medicine	University of Colorado Health Sciences Center

Post-Doctoral Training

07/05 - 06/06	Intern	Internal Medicine	University of California San Diego
07/06 - 06/08	Resident	Internal Medicine	University of California San Diego
07/08 - 06/09	Fellow	Hospice and Palliative Medicine	San Diego Hospice and The Institute for Palliative Medicine
07/09 - 06/12	Fellow	Hematology and Oncology	University of California San Diego

III. CERTIFICATIONS AND LICENSES

Certifications

08/08 - 12/18	Diplomate, Internal Medicine	American Board of Internal Medicine (ABIM)
01/10 -	Diplomate, Hospice and Palliative Medicine	ABIM Certified, Participating in Maintenance of Certification
01/13 -	Diplomate, Medical Oncology	ABIM Certified, Participating in Maintenance of Certification

HELSINN EXHIBIT 2087
Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.
IPR2025-00947

Active and Past Licenses

01/07 - 12/18	Past	California Medical License	98796
03/08 - 04/27	Active	DEA, Schedule II-VI	Available upon request
03/18 - 12/22	Past	Massachusetts Medical License	273842
07/21 - 12/27	Active	Oregon Medical License	205107
01/23 - 01/25	Past	Basic Life Support	American Heart Association
09/23 - 12/25	Past	Washington Medical License	61413587

Formal Faculty Development

2014 - 2015	National Center of Leadership in Academic Medicine	UC San Diego	This program focused on junior faculty to develop skills for an academic career, implement a strategic plan, and network across the university.
2015	Supportive Oncology Workshop	Massachusetts General Hospital	I was selected as a participant in a week-long mentored workshop on protocol development.
2015	Vail Workshop Methods in Clinical Cancer Research	American Society of Clinical Oncology / American Association for Cancer Research	This mentored week-long workshop focuses on developing a clinical trial protocol.
2017	Advanced Certificate in Clinical Research	UC San Diego Extension Clinical Research Enhancement through Supplemental Training	This program focuses on training in research methods, application of these methods, and effective clinical research collaboration (20 units).
2018 - 2019	Education Scholar Program	American Society of Clinical Oncology	I was selected as a participant in the inaugural class of this ASCO international education and leadership program.
2023 - 2024	Oncology Educational Fellowship	Food and Drug Administration and American Association for Cancer Research	This year-long program focused on drug development and regulatory review, including an in-person mock Oncology Drug Advisory Committee (ODAC) meeting at the FDA White Oak Campus.
2025 - 2026	Mid-Career Clinical Leadership Development Program	Oregon Health and Science University	This year-long program enhances leadership skills for mid-career faculty by developing essential competencies, understanding leadership styles, and navigating the OHSU system effectively.

IV. PROFESSIONAL EXPERIENCE

Academic Appointments

07/12 - 04/18	Assistant Professor	Medicine Hematology/Oncology	University of California San Diego Moores Cancer Center
05/18 - 04/21	Assistant Professor	Medicine Hematology/Oncology	Harvard Medical School Massachusetts General Hospital
05/21 - 06/23	Assistant Professor	Medicine Hematology/Oncology	Oregon Health and Science University Knight Cancer Institute
07/23 -	Associate Professor	Medicine Hematology/Oncology	Oregon Health and Science University Knight Cancer Institute

Administrative

06/12 - 07/18	Co-Leader	Palliative Care	University of California San Diego Moores Cancer Center
06/12 - 07/18	Director	Symptom Management Research	University of California San Diego Moores Cancer Center
07/21 - 05/22	Program Director	Melanoma	Oregon Health and Science University Knight Cancer Institute
07/21 -	Program Director	Symptom Science	Oregon Health and Science University Knight Cancer Institute
07/25 -	Program Director	Melanoma	Oregon Health and Science University Knight Cancer Institute

Hospital / Clinical / Professional Appointments

07/12 - 04/18	Assistant Clinical Professor	Internal Medicine Hematology/Oncology	University of California San Diego
05/18 - 04/21	Assistant in Medicine	Internal Medicine Hematology/Oncology	Massachusetts General Hospital
05/21 - 07/23	Assistant Professor	Internal Medicine Hematology/Oncology	Oregon Health and Science University
07/23 -	Associate Professor	Internal Medicine Hematology/Oncology	Oregon Health and Science University

Other Professional Positions

2014 - 2016	Member	Data Safety Committee	Cellceutix Corporation

2016 - 2017	Expert Witness	Alexander v. Scripps Memorial Hospital (Defendant)	Higgs, Fletcher & Mack Superior Court of California Count of San Diego Central Division Case No. 37-2014-00016257-CU-MM-CTL
2016 - 2020	Member	Data Safety Committee	Galera Therapeutics
2017 - 2018	Member	Oncology Advisory Panel, Clinical Guidelines	American Imaging Management Specialty Health
2017 -	Member	Scientific Advisory Board	Napo Therapeutics (NCT04538625) 03/19 - Pre IND meeting 05/25 - FDA Type C Meeting
2019 - 2020	Member	Data Safety Committee	Oragenics
2020 - 2021	Chair	Data Safety Committee	Enzychem Lifesciences
2020 - 2021	Expert Witness	Chappell *ex rel* Estate of Chappell v. UCLA Medical Center (Defendant)	Fraser Watson & Croutch Superior Court of the State of California County of Los Angeles Case No. 19STCV01304 9
2021 -	Member	Scientific Advisory Board	Agilix
2021 -	Member	Scientific Advisory Board	Actimed Therapeutics
2022 -	Member	Scientific Advisory Board	Meter Health
2022 -	Member	Executive Steering Committee	Pfizer (NCT05546476) Phase II study of ponsegromab in patients with NSCLC, pancreatic, and colorectal cancer and cachexia
2023 - 2024	Expert Witness	Heron Therapeutics, Inc (Plaintiff) v. Fresenius Kabi USA, LLC	Paul Hastings District of Delaware Case No. 22-985-WCB
2024 -	Expert Witness	Heron Therapeutics, Inc (Plaintiff) v. Mylan Pharmaceuticals, Inc	Paul Hastings District of Delaware Case No. 23-1015-WCB
2025 -	Chair	Executive Steering Committee	Pfizer (NCT06989437) Phase II/III study of ponsegromab in patients with pancreatic cancer and cachexia
2025 -	Expert Witness	Heron Therapeutics, Inc (Plaintiff) v. Azurity Pharmaceuticals, Inc	Paul Hastings District of Delaware Case No. 24-830-WCB Case No. 24-1363-WCB

V. CONTRIBUTIONS TO DIVERSITY, EQUITY, INCLUSION, AND BELONGING

2015, 2016, 2017, 2018, 2020, 2024	Foro Internacional de Medicina del Dolor y Paliativa	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubrián Universidad Nacional Autónoma de México	As a returning invited faculty member, I teach palliative care-focused topics in English and Spanish to the pain and oncology faculty, trainees, and community clinicians at one of Mexico's few national palliative care training programs.
2021 -	American Society of Clinical Oncology	International Educator for India and Indonesia	I am an active member of the ASCO International Education Committee. I also serve as a faculty educator for ongoing virtual courses focused on resource-limited settings and patients with the highest needs. I have facilitated discussions on palliative care topics, including optimal symptom management, communication, prognostication, and end-of-life care.
2022 -	Co-mentor PI Tibbitts Investigating sex and gender-related differences in immunotherapy treatment effects (NCT06562777)	Building Interdisciplinary Research Careers in Women's Health (BIRCWH) NIH/NIAMS 8K12AR084221	I serve as a co-mentor and research collaborator on Dr. Tibbitts's career development award, a prospective observational study comparing the incidence and severity of immunotherapy-related adverse events (irAEs) between self-identified sex/gender.

VI. SCHOLARSHIP

Area of Research Interest/Scholarly Interest

Symptom Science and Clinical Intervention: My clinical research interest and expertise focus on optimizing symptom management for people living with cancer. My significant scholarly activities and achievements center on identifying, validating, and expanding the number of pharmacologic interventions to minimize treatment-related toxicity and optimize quality of life. My research interests include cancer cachexia, immunotherapy-related adverse events (irAEs), chemotherapy-induced peripheral neuropathy (CIPN), and chemotherapy-induced nausea and vomiting (CINV).

Keywords: symptom science, oncology, drug development, palliative care, cancer cachexia, nausea/vomiting, neuropathy

Grants and Contracts

Total current grants awarded as Principal Investigator (PI) or Co-Principal Investigator (Co-PI)					
Federal	8	Total as PI/Co-PI	4	Total dollar award	$6,190,228
State and Local	21	Total as PI/Co-PI	21	Total dollar award	~$1,500,000
Industry	*15*	*Total as PI/Co-PI*	*15*	*Start-up* *Per-patient*	*$303,943* *$228,909*
Grants	*4*	*Total as PI/Co-PI*	*4*	*Total dollar award*	*$603,876*

Foundations	3	Total as PI/Co-PI	3	Total dollar award	$1,104,000
Total grants awarded as Principal Investigator (PI)					
Federal	2	Total as PI	2	Total dollar award	
State and Local	21				
Industry	*15*	*Total as PI*	*15*	*Start-up* *Per-patient*	*$303,943* *$228,909*
Grants	*3*	*Total as PI*	*3*	*Total dollar award*	*$360,000*
Foundations	2	Total as PI	2	Total dollar award	$210,000
Publications originating from grants and contracts					
Total (n)	12	In-Rank (n) (07/23)	1	First/senior author (n)	6

Federal

Current

2020 - 2025 PATTERN: Patterns and predictors of symptoms, falls, and functioning across treatment and recovery in patients treated with neurotoxic chemotherapy for cancer
Sponsor: NIH/NCI (NCT05790538)
Division of Cancer Prevention 1R01CA226082-01A1
Co-I (PI: Winters-Stone; 0.6 person months per year, $3,139,032)
This study aims to characterize the trajectories of neuropathy symptoms and functioning (objective mobility, physical activity, self-reported functioning, and disability) after receipt of neurotoxic chemotherapy. Additionally, we will determine the simplest patient-centered predictors of symptom and functional trajectories to identify patients who would benefit most from early, targeted interventions. The knowledge gained from this study will identify high-risk patients who may benefit from neurotoxic chemotherapy adjustments and early targeted rehabilitation. We published the protocol in *BMC Cancer* in 2023 (PMID: 37946117).

2023 - 2028 The Pacific Aging and Cancer Studies (PACS): An Infrastructure Advancing the Use of Digital Biomarkers and Related Technologies for Research on Functional Aging and Survivorship in Cancer
Sponsor: NIH/NCI
P30 Supplement CA069533-22S6
Co-I (PI: Winters-Stone; $2,731,196)
This project aims to assess the feasibility of implementing a continuous, passive monitoring platform to describe changes in digital biomarkers of toxicity and symptom trajectories (mobility, cognitive function, sleep, pain, depression) between older and younger patients receiving cancer treatment. We published our findings in patients with hematologic malignancy undergoing autologous hematopoietic stem cell transplantation in *JMIR Cancer* in 2022 (PMID: 36480243).

Completed

2022 - 2024 SWOG S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study Sponsor: NCI/NCTN (NCT04871542)
Site PI (PI: Gunturu; per patient $3,000)
This SWOG-sponsored NCTN study focuses on developing and validating a risk prediction model for grade 3 or high non-hematological immune-related adverse events (irAEs) in the first year of immune checkpoint inhibitor-based therapy for treating solid tumors. Additionally, a translational aim is to develop a cytokine toxicity score derived from 11 cytokine levels as a predictive signature for the development of irAEs.

2015 Alliance A221301: Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial
Sponsor: NCI/NCTN (NCT02116530)
Site PI (PI: Navari; per patient $2,500)
Olanzapine is a second-generation antipsychotic with dopamine and serotonin (D2, 5HT2A, 5HT2C, and 5HT3) neurotransmitter activity, including receptors in the nausea/vomiting pathway. This study evaluated the combination of olanzapine vs placebo with standard chemotherapy-induced nausea and vomiting (CINV) prophylaxis in patients receiving highly emetogenic chemotherapy. Results demonstrated that adding olanzapine improved CINV complete response without severe side effects (*New England Journal of Medicine,* 2016). Olanzapine is now part of all evidence-based guidelines for CINV prophylaxis.

2015 SWOG S1013: Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer-Therapy-EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities
Sponsor: NCI/NCTN (NCT01416688)
Site PI (PI: Baker; per patient $1,000)
This study validated a questionnaire to assess therapy complications, including psychosocial and quality-of-life assessment in patients receiving epithelial growth factor receptor-targeted therapy with skin toxicity (*Journal of Patient-Reported Outcomes* 2020).

2015 - 2016 A Prospective Pilot Study to Evaluate and Correlate Early Lean Muscle Loss with Functional Activity in Metastatic Gastrointestinal and Lung Cancer Patients
Sponsor: NCI/NCTN
Alliance Cancer Control Program Junior Faculty Award #UG1CA189823
PI ($200,000)
This grant supported a prospective, observational study correlating body composition changes per cross-sectional computed tomography (CT) with anthropometric, functional, and patient-reported outcomes (*Supportive Care in Cancer* 2021, PMID: 32990784, first author).

2015 - 2018 Alliance AA221203: Early Palliative Care in Metastatic Gastrointestinal and Lung Cancer Patients
Sponsor: NCI/NCTN (NCT01401907)
Site PI (PI: Temel; per patient $2,500)
Following the groundbreaking palliative care study published in the *New England Journal of Medicine* in 2010, the Alliance proposed a multicenter study evaluating the integration of palliative care within 8 weeks of a metastatic gastrointestinal or incurable lung cancer diagnosis. The University of California San Diego was selected as one of 10 academic sites, and we enrolled 25 patients in the study. Overall, this study demonstrated improved quality of life but had high degrees of missing data, highlighting the challenges of enrolling patients in supportive care trials through an NCTN mechanism (*Journal of Palliative Medicine* 2020, PMID: 32031887).

2017 - 2018 Cancer Clinical Investigator Team Leadership Award
Sponsor: NCI
PI ($120,000)
This grant recognizes and supports outstanding mid-career clinical investigators at NCI-designated cancer centers who improve the lives of people living with cancer through extensive involvement in NCI-funded collaborative clinical trials and whose leadership, participation, and activities promote clinical trials and research. The award provided 15% effort to continue active engagement in symptom interventional clinical trials. Cancer Center Directors nominate each

recipient based on their qualifications, interests, accomplishments, and the nominee's ability to pursue an academic career in clinical research.

National Foundations

2025 - Taking Aim at the Achilles' Heel: Leveraging the Study of Off-Target Immune Toxicities to Improve the Treatment of Patients on Immune Checkpoint Inhibitor Therapy for Cancer.
Sponsor: Kuni Foundation
Co-I (Co-PIs: Molly Thomas, MD, PhD, and Deanne Tibbitts; $100,000)
The blockade of immune checkpoints (PD-1 and CTLA-4) has advanced oncology but is hindered by immune-related adverse events (irAEs), particularly colitis (irColitis). This project hypothesizes that baseline patient factors and CD8+ T cell states can predict irColitis risk. Objectives include: (1) Defining a retrospective irColitis cohort using large language models to identify risk factors; (2) Investigating CD8 T_{RM} cell signatures in tissue as predictors; and (3) Establishing a prospective cohort to assess blood CD8 T cell features related to irColitis risk.

Completed

2012 - 2014 Single-Center, Prospective Feasibility Study Evaluating a Novel Approach to Advance Care Planning in an Outpatient Academic Palliative Care Clinic
American Cancer Society
University of California San Diego Pilot Grant
Principal Investigator ($30,000)
This study evaluated a novel, practical social worker-led advance care planning intervention, assessing the concordance between end-of-life care wishes and actual events. This pilot study (n=34) suggests a focused intervention was feasible and may be sufficient to inform a proxy and achieve end-of-life preferences (*Journal of Palliative Medicine* 2016, PMID: 26826962, Last Author).

2013 - 2018 Positive Outcomes in Cancer Care: Emphasizing Quality of Life and Legacy
American Cancer Society
124667-MRSG-13-233-01-PCSM
Co-Investigator (PI: Montross; $714,000)
Dignity therapy is a psychotherapeutic intervention that helps patients with terminal illnesses review the people and events most meaningful to them and document their legacy to improve the end-of-life experience. I was a Co-I and site PI for this grant, assisting with patient identification and recruitment in our academic palliative care clinic. We successfully referred and enrolled over 50 patients in this study, published in *BMC Palliative Care* [PMID: 26391775].

2016 - 2019 Sojourns Scholar Leadership Program
Cambia Health Foundation
Principal Investigator ($180,000)
This grant's focus is to identify, cultivate, and advance the next generation of palliative care leaders. This program includes multidisciplinary palliative care clinicians and other emerging health system leaders by investing in their professional development. As a Sojourns Scholar, I received funding over two years to protect time for critical leadership skill development and to conduct a prospective observational study of patients with metastatic cancer experiencing weight loss. The project aimed to refine cancer cachexia clinical trial methodology, which we published in *Supportive Care in Cancer* (2021) [PMID: 32990784, first author].

2018 - 2020 Key Outcomes in Palliative Care Chaplaincy
Sponsor: Cambia Health Foundation
Co-I, Co-mentor (PI: Kestenbaum, $180,000)
I mentored a palliative care chaplain in developing a longitudinal database of patient-centered chaplaincy outcomes in palliative care at an academic palliative care clinic. This dataset was used to obtain funding from the Cambia Health Foundation. Allison Kestenbaum, BCC-PCHAC, ACPE, was named the first chaplain recipient of the Sojourns Scholar Leader Award, and we published early findings in the *Journal of Health Care Chaplaincy* [PMID: 34866556, Last Author].

State and Local: Industry

Current

2023 - 2025 Study of the Efficacy and Safety of Ponsegromab in Patients with Cancer, Cachexia, and Elevated GDF-15 (PROACC-1)
Sponsor: Pfizer (NCT05546476)
Executive Steering Committee Member / Site PI (Start-up $20,000, per patient $55,991)
This phase II RCT evaluated the efficacy, safety, and tolerability of ponsegromab, an inhibitor of GDF-15, compared to placebo in patients with cancer, cachexia, and elevated growth differentiation factor -15 (GDF-15). Patients with advanced cancer and elevated concentrations of GDF-15 frequently develop cachexia, which impacts their quality of life and survival. Inhibiting the activity of GDF-15 in such patients may help reverse cachexia and improve their quality of life. We were the highest-enrolling site in North America, and the results were presented at the European Society of Medical Oncology in September 2024, with simultaneous publication in the *New England Journal of Medicine* (PMID: 39282907).

2025 - A Low-Interventional Study to Assess GDF-15 Levels in Adult Participants with Cachexia and Malignant Solid Tumors
Sponsor: Pfizer
Executive Steering Committee Member / Site PI (Start-up $10,000, per patient $1,749)
This low-interventional study aims to measure growth differentiation factor-15 (GDF-15) levels in adults with cachexia and malignant solid tumors in a real-world setting. By enrolling patients across institutions, the study seeks to characterize GDF-15 in individuals with malignant solid tumors, excluding non-small cell lung cancer, pancreatic cancer, and colorectal cancer. The findings may inform the management of patients living with cancer and elevated GDF-15 levels, potentially leading to a significant global impact.

2025 - A Phase 1B Dose-Escalation Study of AV-380 in Combination with Standard-of-Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels
Sponsor: Aveo Pharmaceuticals (NCT05865535)
National PI / Site PI (Start-up $pending, per patient $pending)
This open-label ascending dose study aims to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of AV-380 in patients with metastatic solid tumor cancers experiencing cachexia. AV-380 is an intravenous IgG1 monoclonal antibody designed to bind to circulating human growth differentiation factor 15 (GDF-15), a cytokine implicated in cancer-related cachexia.

Completed

2012 - 2013 Randomized Phase II Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Sponsor: Eli Lilly (NCT01505530)
Site PI (Start-up $17,024; per patient $19,087)
Anti-myostatin antibodies have shown activity in preclinical models of skeletal muscle wasting, including cancer cachexia. LY2495655 is a humanized monoclonal antibody to myostatin, a key regulator of skeletal muscle development. This trial failed to accrue patients due to restrictive inclusion criteria requiring >5% weight loss over the preceding 6 months. Data did not demonstrate any benefit in patients with pancreatic cancer. My experiences with this study made me question existing prospective clinical methods for evaluating novel pharmacologic approaches in treating patients with cancer cachexia (*Journal Cachexia Sarcopenia Muscle* 2018).

2012 - 2015 Phase I Safety Study of LY2787106 in Patients with Cancer and Anemia
Sponsor: Eli Lilly (NCT01340976)
Site PI (Start-up $11,020; per patient $20,319)
Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody may prevent ferroportin internalization, restore cell iron efflux, and allow transferrin-mediated iron transport to the bone marrow. This multicenter phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of a fully humanized monoclonal antibody (LY2787106) targeting hepcidin in patients with cancer and anemia. We enrolled 36% (12 of 33) total patients, presented our findings at the American Society of Hematology 2015 Annual Meeting, and published in the *Journal of Hematology and Oncology* in 2017 (PMID: 28327200, Senior Author).

2012 - 2017 Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
Sponsor: Merck (NCT01254630)
Site PI (Start-up $14,720; per patient $9,086)
Herpes zoster is a common and extremely painful event for patients with cancer. Previous FDA-approved vaccines were contraindicated in patients receiving chemotherapy. This large international study (n=5,286) evaluated a third-generation, gamma-irradiated herpes zoster vaccine for patients with cancer receiving chemotherapy. Results demonstrated that the inactivated varicella-zoster virus (VZV) vaccine was well tolerated and efficacious in preventing VZV in patients with solid tumor cancers receiving chemotherapy [PMID: 31399378].

2013 Anamorelin HcL in the Treatment of Non-Small Cell Lung Cancer Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HcL in Patients with NSCLC-C (ROMANA 1)
Sponsor: Helsinn Healthcare SA (NCT01387269)
Site PI (Start-up $13,670; per patient $11,395)
Preclinical and early-phase clinical trials demonstrated improved lean body mass in patients with cancer cachexia receiving anamorelin, an oral ghrelin analog. This international RCT demonstrated that anamorelin significantly increased lean body mass but did not improve handgrip strength (*Lancet Oncology* 2016). My experiences with this trial catalyzed my interest in evaluating and validating prospective methodologies for cancer cachexia clinical trials to inform clinically meaningful endpoints for regulatory approval.

2013 Anamorelin HcL in the Treatment of Non-Small Cell Lung Cancer Cachexia: An Extension Study (ROMANA 3)
Sponsor: Helsinn Healthcare SA (NCT01395914)
Site PI (Start-up $19,920; per patient $6,676)

This study was an extension study of two phase II, double-blind studies to assess the safety and efficacy of anamorelin in patients with advanced non-small cell lung cancer (NSCLC)-associated cachexia. Treatment-related adverse events were similar in the treatment arm compared to the placebo without any change in regulatory approval (*Annals of Oncology* 2017).

2013 - 2016 Pivotal Phase III Study to Evaluate Overall Survival Using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients with Cachexia
Sponsor: Xbiotech (NCT01767857)
Site PI (Start-up $18,820; per patient $11,825)
Interleukin-1 is a central mediator in cancer cachexia. A phase I study of MABp1, a fully humanized monoclonal antibody to interleukin-1 alpha, showed a promising signal in metastatic colorectal cancer. Yet, accrual to this study was limited by the requirement of>5% weight loss in the preceding 6 months (*Lancet Oncology* 2017). Again, this study fueled my desire to refine prospective methodology in evaluating novel compounds to treat cancer cachexia.

2013 - 2016 A Double-Blind Randomized Three-Armed Phase II Trial of Pledox in Two Different Doses in Combination with FOLFOX6 Compared to Placebo + FOLFOX6 in Patients with Advanced Metastatic Colorectal (Stage IV) Cancer (PLIANT Study)
Sponsor: Pled Pharma (NCT01619423)
Site PI (Start-up $18,670; per patient $20,905)
This international phase II study evaluated calmangafodipir (a superoxide dismutase mimetic and iron chelator) to prevent chemotherapy-related neutropenia and oxaliplatin-induced peripheral neuropathy. The phase II results were promising but lacked phase III data (*Acta Oncology* 2018).

2015 - 2017 Observational Study of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Multiday Highly Emetogenic Chemotherapy (HEC) Regimens for Hematological Malignancies
Sponsor: Vector Oncology
Site PI (Start-up $7,000; per patient $1,500)
Evidence-based prophylaxis to prevent CINV in hematologic malignancy patients who receive multiday chemotherapy is lacking. This observational study aimed to collect information regarding clinician antiemetic prescribing patterns and patients' daily CINV experience.

2016 - 2017 Phase II, Randomized, Single-Center, Pilot Feasibility Study to Evaluate Naloxegol for Opioid-Induced Constipation in Cancer Patients
Sponsor: AstraZeneca (IND 160121, NCT02745353)
Principal Investigator (Start-up $27,106; per patient $3,320)
Opioid-induced constipation (OIC) is a common and distressing symptom for patients with cancer requiring burdensome self-titration of laxatives for prophylaxis and treatment. This proposed trial assessed the use of naloxegol in cancer-related OIC, utilizing an open-label crossover study compared to stimulant laxatives. Naloxegol, a peripherally selective opioid antagonist (PAMORA), was evaluated and approved in the non-cancer setting, but a randomized controlled trial in cancer failed to accrue. The primary aim of feasibility was not achieved.

2017 - 2018 Fixed-Dose Combination of Netupitant and Palonosetron (Akynzeo) in the Treatment of Refractory Chemotherapy-Induced Nausea and Vomiting
Sponsor: Helsinn Healthcare SA (IND 161691, NCT03008213)
PI (Start-up $27,404; per patient $3,575)
The primary aim of this phase II, open-label study was to determine the feasibility of using a fixed-dose combination of netupitant and palonosetron (Akynzeo) for the treatment of refractory CINV that occurs during subsequent chemotherapy cycles when prophylactic and rescue antiemetics are ineffective. The trial was closed early due to my departure from UC San Diego.

2017 - 2018 Phase II, Open-Label Study to Evaluate Lazanda in Cancer Patients Receiving Palliative Radiation Vomiting
Sponsor: Depomed (IND 161263, NCT03071744)
PI (Start-up $11,574; per patient $3,467)
In this phase II open-label study, we evaluated intranasal fentanyl as a premedication for patients receiving hypofractionated radiation for painful bony metastases. We enrolled 6 patients with improved tolerance to radiation treatments and decreased pain. The trial was terminated early due to my departure from UC San Diego.

2021 - 2022 A 6-Week, Randomized, Double-Blind, Sponsor-Open Study to Assess the Effect of Repeated Subcutaneous Administration of PF-06946860 on Appetite in Participants with Advanced Cancer and Anorexia, Followed by an 18-week Open-Label Treatment Period (C3651010).
Sponsor: Pfizer (NCT04803305)
Site PI (Start-up $28,834, per patient $32,008)
In this phase Ib study, the effects of PF-06946860 versus placebo were evaluated on cancer-associated anorexia and weight loss across various solid tumor cancers. This study's primary aim was to assess the effects of repeated subcutaneous administration of PF-06946860—a recombinant humanized monoclonal antibody directed against the cytokine growth differentiation factor 15 (GDF-15)—on appetite in people with advanced cancer, anorexia, and elevated circulating GDF-15 levels (*Clinical Cancer Research* 2024). I presented this study at the European Society of Medical Oncology 2021; later, we participated in the phase II RCT.

2022 - 2024 ONTARGET: A Phase 3 multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients with Solid Tumors Receiving Targeted Cancer Therapies with or without Standard Chemotherapy (NP303-102).
Sponsor: Napo Pharmaceuticals (NCT04538625)
Executive Steer Committee, Co-I, Site PI (PI: Okhuysen; Start-up $32,316, per patient $16,713)
This phase III study compared crofelemer with placebo to prevent diarrhea caused by tyrosine kinase inhibitors (TKIs) across various cancers, focusing on over 20 FDA-approved TKIs that cause diarrhea in more than 50% of patients. Crofelemer is an FDA-approved antidiarrheal that modulates chloride-ion activity in the intestine and has established safety with no drug interactions. The study enrolled 15 participants from the OHSU Knight Cancer Institute in July 2023. Although the primary aim was not met, a prespecified analysis found that patients with breast and lung cancer benefited from crofelemer over placebo, with results presented at the San Antonio Breast Cancer Symposium 2024.

2022 - 2024 A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating, Multicenter, Phase I Study to Assess the Safety and Tolerability of ART-123 in Combination with Leucovorin/5-Fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients (ART-123.PN101)
Sponsor: Veloxis Pharmaceuticals (NCT05251727)
US National Lead PI / Site PI (Start-up $35,864, per patient $13,042)
This phase I study assessed the safety and tolerability of ART-123 combined with first-line FOLFOX and bevacizumab in patients with metastatic colorectal cancer, including those with resected and intact primary tumors. ART-123, a recombinant human soluble thrombomodulin approved in Japan for sepsis, may help prevent oxaliplatin-induced peripheral neuropathy by activating thrombin activatable fibrinolysis inhibitor (TAFI) and protein C, and inactivating high-mobility group box 1 protein (HMGB1). A prior phase II study in 80 patients showed ART-123's potential in delaying and reducing OIPN during adjuvant FOLFOX, necessitating further validation in the metastatic setting.

2022 - 2025 Study of the Efficacy and Safety of Ponsegromab in Patients with Cancer, Cachexia, and Elevated GDF-15 (PROACC-1).
Sponsor: Pfizer (NCT05546476)
Site PI (Start-up $28,834, per patient $32,008)
This phase II study evaluated 3 doses of ponsegromab (a monoclonal antibody targeting growth differentiation factor 15 [GDF-15]) versus placebo in patients with lung, pancreatic, or colorectal cancer with elevated GDF-15 levels and ongoing weight loss. This study's primary aim was to assess the effects of ponsegromab on weight loss. Secondary endpoints included appetite and cachexia symptoms; exploratory endpoints included skeletal muscle, digital measures of physical activity, and safety. Patients receiving the highest dose of ponsegromab (400mg SC monthly) experienced an average 6.2-pound weight gain over 12 weeks with improved appetite, cachexia symptoms, skeletal muscle, and physical activity with demonstrated safety. This study was presented at the European Society of Medical Oncology 2024 and simultaneously published in the *New England Journal of Medicine* (PMID: 39282907).

State and Local: Grants

Current

2023 - INSITE: Investigating Sex and Gender-related Differences in Immunotherapy Treatment Effects
Sponsor: NIH/NIAMS (NCT06562777)
Building Interdisciplinary Research Careers in Women's Health (BIRCWH) #8K12AR084221
Co-I, Co-mentor (PI: Tibbitts; $243,876)
I serve as a collaborator and research mentor on Dr. Tibbitts's career development award, a prospective observational study comparing the incidence and severity of immunotherapy-related adverse events (irAEs) between self-identified men and women. Currently, 55 of 90 participants have enrolled.

2024 - ACTO: A Phase II, Pilot Randomized Trial of Olanzapine in the Treatment of Cancer Cachexia
Sponsor: NIH/NCI (NCT05705492)
NCI-2022-10209 Cancer Support Grants #P30CA069533
PI ($50,000)
This ongoing randomized, placebo-controlled phase II study evaluates the impact of olanzapine vs placebo on anorexia, weight gain, and quality of life in patients with advanced cancer. Interdisciplinary and intra-programmatic collaborators include Kerri Winters-Stone, PhD, and Teresa Zimmers, PhD. It is sponsored by the NCI and Knight Cancer Institute Philanthropic funds.

Completed

2013 - 2016 Single-center, Prospective Expansion Study Evaluating Advance Care Planning Discussions Utilizing a Novel Approach as Performed by a Palliative Care Pharmacist
Sponsor: In-kind
PI
Building upon our previous social-worker-led intervention, I supervised a palliative care pharmacist (Co-I Joseph Ma, PharmD) in a single institution study to evaluate his expanded role as a facilitator of advance care planning, including concordance of end-of-life care wishes and actual events. We published our experience with this pharmacist-led intervention in the *Journal of Oncology Practice* (2021) [PMID: 33417492, Last Author].

2014 - 2015 Prospective Pilot Study to Evaluate Early Skeletal Muscle Loss and Correlation with Functional Activity in Cancer Patients Using Actigraphy

Sponsor: University of California San Diego Academic Senate Research Bridge Grant
PI ($10,000)
With this institutional grant, I collected preliminary feasibility information regarding the use of actigraphy in patients with incurable cancer and cachexia. Despite the research team's engagement and support, participants did not adhere to the wear requirements due to practical challenges and perceived burden. I learned the importance of including a physical function and activity expert when using actigraphy in clinical trials to address the practical challenges of collecting these data.

2016 - 2018 FIT: Functional and Imaging Testing to Evaluate Body Composition and Functional Activity in Metastatic Cancer Patients
Sponsor: University of California San Diego Clinical Translational Research Institute
Career Development Award #KL2TR001444 L30 CA199550
PI ($300,000)
This grant supported my career development by enabling me to complete a prospective observational study of patients with advanced cancer receiving chemotherapy. The study aimed to correlate changes in body composition on cross-sectional CT scans with anthropometric, functional, and patient-reported outcomes (PROs). We did not observe any association between weight changes and functional outcomes or PROs. Yet, greater skeletal muscle loss was associated with a greater decline in physical function [PMID: 32990784, first author].

Publications

Peer-reviewed publication metrics					
ORCID 0000-0002-3674-3573					
Total number	113	Total 1st author (n)	33	Total senior author (n)	18
In-rank (since 07/23)	29	In-rank 1st author (n)	4	In-rank senior author (n)	2
Indices					
h-index	29	Median RCR	0.88	NCBI My Bibliography	

Peer-Reviewed Journal Publications

1. Garcia RA, **Roeland EJ**, Godwin HA. Regulation of synaptotagmin functions via C2 domains. J Inorganic Bichochem. 1999 Apr; 74(1-4): 135.
2. **Roeland E**, von Gunten CF. Current concepts in malignant bowel obstruction management. Curr Oncol Rep. 2009 July; 11(4): 298-303 (PMID: 19508835).
3. **Roeland E**, Mitchell W, Elia G, Thornberry K, Herman H, Cain J, Atayee R, Bardwell W, von Gunten CF. Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 1: physical symptoms. J Support Oncol. 2010 May-Jun; 8(3): 100-16 (PMID: 20552923).
4. **Roeland E**, Mitchell W, Elia G, Thornberry K, Herman H, Cain J, Atayee R, Bardwell W, von Gunten CF. Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 2: psychosocial concerns. J Support Oncol. 2010 Jul-Aug; 8(4): 179-83 (PMID: 20822037).
5. Hwang M, Pirrello R, Pu M, Messer K, **Roeland E**. Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital. Support Care Cancer. 2013 Oct; 21(10): 2817-24 (PMID: 23732621).
6. Ma JD, Horton JM, Huang M, Atayee RS, **Roeland E**. A single-center, retrospective analysis evaluating the utilization of the opioid risk tool in opioid-treated cancer patients. J Pain Palliat Care Pharmacother. 2014 Jan; 28(1): 4-9 Jan 13 (PMID: 24417217).

7. Wong-Sefidian I, Ale-Ali A, Demoor P, Martinez S, Curtin P, Lane T, **Roeland E**. Implementing inpatient evidence-based antihistamine transfusion premedication guidelines at a single academic US hospital. J Community Support Oncol. 2014 Feb; 12(2): 56-64 (PMID: 24971406).
8. **Roeland E**, Cain J, Onderdonk C, Kerr K, Mitchell W, Thornberry K. When open-ended questions don't work—the role of palliative paternalism in difficult medical decisions. J Palliat Med. 2014 Apr; 17(4): 415-420 (PMID: 24588626).
9. Ma JD, Heavey SF, Revta C, **Roeland EJ**. Novel investigational biologics for the treatment of cancer cachexia. Expert Opin Biol Ther. 2014 Aug; 14(8): 1113-20 (PMID: 24707881).
10. Wong J, Xu B, Yeung HN, **Roeland EJ**, Martinez ME, Le QT, Mell LK, Murphy JD. Age disparity in palliative radiotherapy among patients with advanced cancer. Int J Radiat Oncol Biol Phys. 2014 Sept 1; 90(1): 224-30 (PMID: 25195994).
11. Yeung HN, Mitchell WM, **Roeland EJ**, Xu B, Mell LK, Le QT, Murphy JD. Palliative radiation before hospice: the long and the short of it. J Pain Symptom Manage. 2014 Dec; 48(6): 1070-1079 (PMID: 24819083).
12. Bruggeman AR, Heavey SF, Ma JD, Revta C, **Roeland EJ**. Lack of documentation of evidence-based prognostication in cancer patients by inpatient palliative care consultants. J Pall Med. 2015 Apr; 18(4): 382-385 (PMID: 25608220).
13. Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, **Roeland EJ**, Lowy AM. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Annals of Surg Oncol. 2015 May; 22(5): 1716-1721 (PMID: 25145504).
14. Langley-DeGroot, Ma JD, Hirst J, **Roeland EJ**. Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature. J Pain Palliat Care Pharmacother. 2015 Jun; 29(2): 148-52 9PMID: 26095486).
15. Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein J, Choi J, Beamer L, **Roeland E**, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Supportive Care in Cancer. 2015 Aug; 23(8): 2231-44 (PMID: 25564221).
16. Lin KJ, Ching A, Edmonds KP, **Roeland EJ**, Revta Ca, Ma JD, Atayee RS. Variable patterns of continuous morphine infusions at the end of life. J Palliat Med. 2015 Sep;18(9):786-9 (PMID: 26107143).
17. Chang A, **Roeland EJ**, Atayee RS, Revta C, Ma JD. Transmucosal immediate-release fentanyl for breakthrough cancer pain: opportunities and challenges for use in palliative care. J Pain Palli Care Pharm. 2015 Sep; 29(3): 247-60 (PMID: 26368648).
18. Montross-Thomas LP, Irwin SA, Meier EA, Gallegos JV, Golshan S, **Roeland E**, McNeal H, Munson D, Rodseth L. Enhancing legacy in palliative care: study protocol for a randomized controlled trial of dignity therapy focused on positive outcomes. BMC Palliative 2015 Sep 21;14:44 (PMID: 4578680).
19. **Roeland E**, Ku G. Spanning the canyon between stem cell transplantation and palliative care. Hematology Am Soc Hematol Educ Program. 2015: 484-9 (PMID: 26627762).
20. **Roeland E**, Aapro MS, Schwartzberg LS. Advances in the management of chemotherapy-induced nausea and vomiting: new data from recent and ongoing trials. Clin Advances Hema Onc. 2015 October; 13(10): 3-13 (PMID: 26859507).
21. Gramling R, Stanek S, Ladwig S, Gajary-Coots E, Cimino J, Anderson W, Norton SA, Aslakson RA, Ast K, Elk R, Garner KK, Grudzen C, Kamal AH, Lamba S, LeBlanc TW, Rhodes RL, **Roeland E**, Schulman-Green D, Unroe KT. Feeling heard and understood: a patient-reported quality measure for the inpatient palliative care setting. J Pain Symptom Manage. 2016 Feb; 51(2): 150-4 (PMID: 26596879).
22. Ma JD, Benn M, Nelson SH, Campillo A, Heavey SF, Cramer A, Revta C, Thornberry K, **Roeland EJ**. Exploring the definition of an informed health care proxy. J Palliat Med. 2016 Mar; 19(3):250-1. 2 (PMID: 26836962).
23. Kamal AH, Bull J, Ritchie CS, Kutner JS, Hanson LC, Friedman F, Taylor DH, Aslakson RA, Ast K, Elk R, Garner KK, Gramling R, Grudzen C, Lamba S, LeBlanc TW, Rhodes RL, **Roeland E**, Schulman-Green D, Unroe KT. Adherence to measuring what matters using point-of-care data collection across diverse clinical settings. J Pain Symptom Manage. 2016 Mar; 51(3):497-503 (PMID: 26854995).

24. Grudzen CR, Buonocore P, Steinberg J, Ortiz JM, Richardson LD, Aslakson RA, Ast K, Elk R, Garner KK, Gramling R, Grudzen C, Kamal AH, Lamba S, LeBlanc TW, Rhodes RL, **Roeland E**, Schulman-Green D, Unroe KT. Concordance of advance care plans with inpatient directives in the electronic medical record for older patients admitted from the emergency department. J Pain Symptom Manage. 2016 Apr; 51(4): 647-51 (PMID: 26891604).
25. **Roeland EJ**, Triplett DP, Matsuno RK, Boero IJ, Hwang L, Yeung HN, Mell L, Murphy JD. Patterns of palliative care consultation among elderly cancer patients. J Natl Compr Canc Netw. 2016 Apr; 14(4):439-45. (PMID: 27059192).
26. Kronenberg DG, Hagmann CH, Ma JD, Revta C, Armstrong J, **Roeland EJ**. The default dilemma: code status regardless of medical context. J Pall Med. 2016 Nov; 19(11): 1134. 2016 Aug 8 (PMID: 27500355).
27. Bruggeman A, Kamal AH, LeBlanc TW, Ma JD, Baracos V, **Roeland EJ**. Cancer cachexia: beyond weight loss. J Onc Pract. 2016 Nov; 12(11): 1163-1171 (PMID: 27858548).
28. **Roeland EJ**, Ma JD, Nelson SH, Seibert T, Heavey S, Revta C, Gallivan A, Baracos VE. Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. Support Care Cancer. 2017 Feb;25(2):365-369 (PMID: 27628947).
29. Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL Jr, Tiu RV, Wang X, Callies S, Cox J, Tuttle JL, Lau YK, **Roeland EJ**. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73 (PMID: 28327200).
30. Martin EJ, **Roeland EJ**, Sharp M, Revta C, Murph JD, Fero KE, Yeung HN. Patient-controlled analgesia for cancer-related pain: clinical predictors of patient outcomes. J Natl Compr Canc Netw. 2017 May; 15(5): 595-600 (PMID: 28476739).
31. Dranitsaris G, Molassiotis A, Clemons M, **Roeland E**, Schwartzber L, Dielenseger P, Jordan K, Young A, Aapro M. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Annals Oncol. 2017 Jun 1;28(6):1260-1267 (PMID: 28398530).
32. Berger MJ, Ettinger DS, Aston J, Barbour S, Bersbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Labell LM, Noonan K, **Roeland E**, Rugo HS, Schwartzberg LS, Scullion B, Tomeuy J, Todaro B, Urba SG, Shead DA, Hughs M. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017 Jul; 15(7): 883-893 (PMID: 28687576).
33. Wang WS, Ma JD, Nelson SH, Revta C, Buckholz GT, Mulroney CM, **Roeland E**. Advance care planning and palliative care integration for hematopoietic stem cell transplant patients. J Onc Pract 2017 Sep; 13(9): e721-e728 [PMID: 28644706].
34. Triplett DP, LeBrett WG, Bryant AK, Bruggeman AR, Matsuno RK, Hwang L, Boero IJ, **Roeland EJ**, Yeung HN, Murphy JD. Impact of palliative care on the aggressiveness of end-of-life care among patients with advanced cancer. J Oncol Pract 2017 Sep; 13(9): e760-e769 (PMID: 28829693).
35. **Roeland E**, Hagmann C, Dullea A, Madlensky L. Addressing hereditary cancer risk at the end of life. J Oncol Pract 2017 Oct; 13(10): e851-e856 (PMID: 28541788).
36. Wiesenthal AC, Patel SP, LeBlanc TW, **Roeland EJ**, Kamal AH. Top ten tips for palliative care clinicians caring for cancer patients receiving immunotherapy. J Palliat Med. 2018 May;21(5):694-699 (PMID: 29658821).
37. Wang WS, Ma JD, Nelson SH, Revta C, Buckholz GT, Mulroney C, **Roeland EJ**. Transfusion practices at the end of life for hematopoietic stem cell transplant patients. Support Care Cancer. 2018 Jun; 26(6):1927-1931 (PMID: 29285557).
38. Ma JD, El-Jawahri AR, LeBlanc TW, **Roeland EJ**. Pain syndromes and management in adult hematopoietic stem cell transplantation. Hematol Oncol Clin North Am. 2018 June; 32(3): 551-567 (PMID: 29729788).
39. Schwartzberg L, **Roeland E**, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla RJ, Karthaus M. Phase III safety study of intravenous NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018 Jul 1;29(7):1535-1540 (PMID: 29722791).

40. Hagmann C, Cramer A, Kestenbaum A, Durazo C, Downey A, Russell M, Geluz J, Ma JD**, Roeland EJ**. Evidence-based palliative care approaches to non-pain physical symptom management in cancer patients. Semin Oncol Nurs. 2018 Aug; 34(3): 227-240 (PMID: 30120000).
41. Yau WH, **Roeland EJ**, Revta C, Ale-Ali A, Ma JD. Opioid and benzodiazepine relative use in breast cancer patients before, during, and after chemotherapy. J Pain Palliat Care Pharmacother. 2018 Sep 11:1-3 (PMID: 30204508).
42. El-Jawahri A, LeBlanc TW, Burns LJ, Denzen E, Meyer C, Mau LW, **Roeland EJ**, Wood WA, Petersdorf E. What do transplant physicians think about palliative care? A national survey study. Cancer. 2018 Dec 01; 124(23):4556-4566 (PMID: 30289980).
43. Constance D, Sanders J, Calton B, DeSanto-Madeya S, Donesky D, Lakin JR, **Roeland E**, Scherer JS, Walling A, Williams B. The Cambia Sojourns Scholars leadership program: projects and reflections on leadership in palliative care. J Palliat Med. 2019 Jul; 22(7): 823-829. 27 (PMID: 30810459).
44. Parikh AR, Leschiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, **Roeland E**, Ryan DP, Weeks CD, Kwak EL, Faris JE, Wo JY Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 Sep; 25(9): 1415-1421 (PMID: 31501609).
45. Webb JA, Foxwell AM, Jones CA, El-Jawahri A, Kamal AH, Kayastha N, **Roeland EJ**, LeBlanc TW. Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Hematologic Malignancies. J Palliat Med. 2019 Nov; 22(11): 1449-1454 (PMID: 31329005).
46. **Roeland EJ**, Lindley LC, Gilbertson-White S, Saeidzadeh S, Currie ER, Friedman S, Bakitas M, Mack JW. End-of-life care among adolescent and young adult cancer patients living in poverty. Cancer 2020 Feb 15; 126(4): 886-893 (PMID: 31724747).
47. Navari RM, Ruddy KJ, LeBlc TW, Clark-Snow R, Wickham RJ, Binder G, Coberly T, Potluri R, Schmerold LM, **Roeland EJ**. Impact of the addition of carboplatin AUC ≥ 4 to antiemetic guidelines for triple antiemetic prophylaxis: A gap in quality of care, guideline adoption, and avoiding acute care. JCO Oncol Pract 2020 Feb; 16(2): e132-e138 (PMID: 318000352).
48. Temel JS, Sloan J, Zemia T, Greer JA, Jackson VA, El-Jawahri A, Kamdar M, Kamal A, Blinderman CD, Strand J, Zylla D, Daugherty C, Furgan M, Obel J, Razqa M, **Roeland EJ**, Loprinzi C. Multisite, randomized trial of early integrated palliative care and oncology care in the patients with advanced lung and gastrointestinal cancer: Alliance A221303. J Palliat Med. 2020 Feb 7; 23(7): 922-929 (PMID: 32031887).
49. Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, **Roeland E**. Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline/cyclophosphamide (AC) chemotherapy. Oncologist 2020 Mar; 25(3): e589-e597 (PMID: 32162813).
50. Troschel AS, Troschel FM, Best TD, Gaissert HA, Torriani M, Muniappan A, van Seventer EE, Nipp RD, **Roeland EJ**, Temel JS, Fintelmann FJ. Computed Tomography-based Body Composition Analysis and Its Role in Lung Cancer Care. J Thorac Imaging. 2020 Mar; 35(2): 91-100 (PMID: 31268959).
51. **Roeland EJ**, Sera CJ, Ma JD. More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer. Supportive Care in Cancer. 2020 Apr; 28(4): 1793-1797 (PMID: 31332514).
52. van Seventer EE, Fintelmann FJ, **Roeland EJ**, Nipp RD. Leveraging the potential synergy between patient-reported outcomes and body composition analysis in patients with cancer. Oncologist 2020 Apr; 25(4): 271-273 (PMID: 31957940).
53. Li, SS, Udelsman BV, Parikh A, Klempner SJ, Clark JW, **Roeland EJ**, Wo JY, Hong TS, Mullen JT. Impact of postoperative complications and completion of multimodality therapy on survival in patients undergoing gastrectomy for advanced gastric cancer. J Am Coll Surg. 2020 Jun; 230(6): 912-924 (PMID: 32035978).

54. **Roeland EJ**, Ruddy KJ, LeBlanc TW, Nipp RD, Binder G, Sebastiani S, Potluri R, Schmerold L, Papademetriou E, Schwartzberg L, Navari RM. What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. J Natl Compr Canc Netw. 2020 Jun; 18(6): 676-681 (PMID: 32502985).
55. **Roeland EJ**, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL. Management of cancer cachexia: ASCO Guideline. J Clin Oncol. 2020 July 20; 38(21): 2488-2453 20 (PMID: 32432946).
56. Navari RM, **Roeland EJ**. Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncol. 2020 Aug; 16(24): 1863-1872 (PMID: 32543309).
57. Chaudhary S, Kwak EL, Hwang KL, Lennerz JK, Corcoran RB, Heist RS, Russo AL, Parikhj AP, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, Azzoli CG, **Roeland EJ**, Goyal L, Allen J, Mullen JT, Ryan DP, Iafrate AJ, Klempner SJ, Clark JW, Hong TS. Revisiting MET: clinical characteristics and treatment outcomes of patients with locally advanced or metastatic, MET-amplified esophagogastric cancers. Oncologist. 2020 Nov; 25(11): e1691-e1700 (PMID: 32820577).
58. Aapro M, Navari RM, **Roeland E**, Zhang Li, Schwartzberg L. Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: a review of phase 3 studies. Critical Reviews in Oncology/Hematology. 2021 Jan; 157: 103143 (PMID: 33260048).
59. van Seventer E, Marquardt PJ, Troschel AS, Best TD, Horick N, Azoba C, Newcomb R, **Roeland EJ**, Rosenthal M, Bridge CP, Greer JA, El-Jawahri A, Temel J, Fintelmann FJ, Nipp RD. Associations of skeletal muscle with symptom burden and clinical outcomes in hospitalized patients with advanced cancer. J Natl Compr Canc Netw. 2021 Jan 29; 1-9 (PMID: 33513564).
60. van Seventer EE, Fish MG, Fosbenner K, Kanter K, Mojtahed A, Allen JN, Blaszkowsky, Clark JW, Dubois J, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, **Roeland EJ**, Ryan DP, Weekes CD, Mulvey T, El-Jawahri A, Horick N, Corcoran RB, Parikh AR, Nipp RD. Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. Cancer. 2021 Feb 15; 127(4): 619-627 (PMID: 33170962).
61. Ma JD, Dullea A, Hagmann C, Friedman S, Russell M, Cramer A, Benn M, **Roeland EJ**. Exploring the expanded role of pharmacists in advance care planning. JCO Oncol Pract. 2021 Feb 17(2): 102-106 (PMID: 33417492).
62. Hui D, Bohlke K, Bao T, Campbell TC, Coyne PJ, Currow DC, Gupta A, Leiser A, Mori M, Nava S, Reinke L, **Roeland EJ**, Seigel C, Walsh D, Campbell M. Management of dyspnea in advanced cancer: ASCO Guideline. J Clin Oncol. 2021 Apr 20; 39(12): 1389-1411 (PMID: 33617290).
63. **Roeland EJ**, Phull H, Hagmann C, Sera C, Dullea A, El-Jawahri A, Nelson S, Galivan A, Ma JD, Nipp RD, Baracos VE. FIT: Functional and image testing in patients with metastatic cancer. Support Care in Cancer. 2021 May; 29(5): 2771-2775 (PMID: 32990784).
64. Best TD, **Roeland EJ^**, Horick NK, van Seventer EE, El-Jawahri A, Troschel AS, Johnson PC, Kanter KN, Fish MG, Marquardt JP, Bridge CP, Temel JS, Corcoran RB, Nipp RD, Fintelmann FJ. Muscle loss is associated with overall survival in patients with metastatic colorectal cancer independent of tumor mutational status and weight loss. Oncologist. 2021 June; 26(6): e963-970 (PMID: 33818860). (^Co-first authorship).
65. Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari S, Roeland EJ. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23): 3027-3035 (PMID: 33878896)
66. Mansoor W, **Roeland EJ**, Chaudhry A, Liepa AM, Wei R, Knoderer H, Abada P, Chatterjee A, Klempner SJ. Early weight loss as a prognostic factor in patients with advanced gastric cancer: analyses from REGARD, RAINBOW, and RAINFALL phase III studies. Oncologist. 2021 Sep; 26(9): e1538-1547 (PMID: 34037286).
67. Sheridan PE, LeBrett WG, Triplett DP, **Roeland EJ**, Bruggeman AR, Yeung HN, Murphy JD. Cost savings associated with palliative care among older adults with advanced cancer. Am J Hosp Palliat Care. 2021 Oct; 38(10): 1250-1257 (PMID: 33423523).
68. Parikh AR, van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, Kanter K, Fish MG, Fosbenner KD, Miao B, Phillips S, Carmichael JH, Sharma N, Jarnagin J, Baiev I, Shah YS, Fetter IJ, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Dubois JS, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, Nipp RD, **Roeland EJ**,

Ryan DP, Weekes CD, Wo JY, Hong TS, Bordeianou L, Ferrone CR, Qadan M, Kunitake H, Berger D, Ricciardi R, Cusack JC, Raymond VM, Talasaz M, Boland GM, Corcoran RB. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in colorectal cancer patients. Clin Cancer Res. 2021 Oct 15 (PMID: 33926918).

69. Gupta A, Khalid O, Ladnier D, Moravek C, Lamkin A, Matrisian LM, Doss S, Denlinger CS, Coveler AL, Weekes CD, **Roeland E**, Hendifar AE, Nipp RD. Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) Online Patient Registry Experience. Cancer Med. 2021 Oct; 10(2): 7152-7161 (PMID: 34477302).
70. Wo J, Clark J, Eyler C, Mino-Kenudson M, Klempner S, Allen J, Keane F, Parikh A, **Roeland E**, Drapek L, Ryan D, Corcoran R, van Seventer E, Fetter I, Shahzade H, Khandekar M, Lanuti M, Morse C, Heist R, Ulysse C, Christopher B, Baglini C, Yeap B, Mullen J, Hong T. Results and molecular correlates from a pilot study of neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal adenocarcinomas. Clin Cancer Res. 2021 Dec 1; 27(23): 6343-6353 (PMID: 34330715).
71. Umaretiya PJ, Ilowite M, Fisher L, Bakitas M, Currie ER, Gilbertson-White S, Lindley L, **Roeland E**, Mack WJ, Bona K. Missing voices: Lessons learned from non-participating caregivers in palliative care research. J Adolesc Young Adult Oncol. 2021 Dec 6 (PMID: 34870475).
72. Kanter K, Fish M, Mauri G, Horick NK, Allen JN, Blaszkowsky LS, Clark JW, Ryan DP, Nipp RD, Giantonio BJ, Goyal L, Dubois J, Murphy JE, Franses J, Dlempner SJ, **Roeland EJ**, Weeks CD, Wo JY, Hong TS, van Seventer EE, Corcoran RB, Parikh AR. Care patterns and overall survival in patients with early-onset metastatic colorectal cancer. JCO Oncol Pract. 2021 Dec; 17 (12): e1846-e1855 (PMID: 34043449).
73. Kestenbaum A, McEniry KA, Friedman S, Kent J, Ma JD, **Roeland EJ**. Spiritual AIM: assessment and documentation of spiritual needs in patients with cancer. J Health Care Chaplain. 2021 Dec 5; 1-12 (PMID: 34866556).
74. Uchida E, Lei MM, **Roeland E**, Lou U. Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab. J Oncol Pharm Pract. 2022 Jan; 28(1): 119-126 (PMID: 33435826).
75. Kim DW, Lee G, Hong TS, Li G, Horick NK, **Roeland E**, Keane FK, Eyler C, Drapek LC, Ryan DP, Allen JN, Berger D, Parikh AR, Mullen JT, Klempner SJ, Clark JW, Wo JY. ASO Visual Abstract: Neoadjuvant versus postoperative chemoradiotherapy is associated with improved survival for patients with resectable gastric and gastroesophageal cancer. Ann Surg Oncol. 2022 Jan; 29(1): 242-252 (PMID: 34490285).
76. Marquardt JP, **Roeland EJ,** Van Seventer EE, Best TD, Horick NK, Nipp RD, Fintelmann FJ. Percentile-based averaging and skeletal muscle gauge improve body composition analysis: validation at multiple vertebral levels. J Cachexia, Sarcopenia and Muscle. 2022 Feb; 13(1): 190-202 (PMID: 34729952).
77. Navari R, Binder G, Molasiotis A, Herrstedt J, **Roeland EJ**, Ruddy KJ, LeBlanc TW, Kloth DD, Klute KA, Papademetriou E, Schmerold L, Schwartzberg L. Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of recurrent CINV in later cycles. Oncologist. 2022 Mar 17; 28(3): 208-213 (PMID: 36527702).
78. Currie ER, Johnston EE, Bakitas M, **Roeland E**, Lindley LC, Gilbertson-White S, Mack J. Caregiver-reported quality of end-of-life care of adolescent and young adult decedents with cancer. J Palliat Care. 2022 Apr; 37(2): 87-92 (PMID: 33752501).
79. Garcia JM, Dunne RF, Santiago K, Martin L, Birnbaum MJ, Crawford J, Hendifar AE, Kochanczyk, Moravek C, Piccinin D, Picozzi V, **Roeland EJ**, Selig WKD, Zimmers TA. Addressing unmet needs for people with cancer cachexia: recommendations from a multi-stakeholder workshop. J Cachexia Sarcopenia Muscle. 2022 Apr; 13(2): 1418-1425 (PMID: 35218313).
80. Dunne RF, **Roeland EJ**. The interplay amongst pancreatic cancer, cachexia, body composition, and diabetes. Hematol Oncol Clin North Am. 2022 Sep 22; S0889-8588 (PMID: 36154783).
81. Nipp RD, Gauferb E, Vyas C, Azoba C, Qian CL, Jaggers J, Weekes CD, Allen JN, **Roeland EJ**, Parikh AR, Miller L, Yo JY, Hennessey Smith M, Brown P, Shulman E, Fernandez del Castillo C, Kimmelmann AC, Ting D, Hong TS, Greer JA, Ryan DP, Temel JS, El-Jawahri A. Supportive oncology care at home intervention for patients with pancreatic cancer. JCO Oncol Pract. 2022 Oct; 18(10): e1587-e1593 (PMID: 35830625).

82. Skiba MB, Harker GR, Guidarelli C, El-Gohary M, Horack F, **Roeland EJ**, Silbermann R, Hayes-Lattin B, Winters-Stone K. Using wearable inertial sensors to assess mobility of hematological cancer patients and associations with chemotherapy-related symptoms prior to autologous hematopoietic stem cell transplant. JMIR Cancer. 2022 Dec 8; 8(4): e39271 (PMID: 36480243).
83. Aapro M, Jordan K, Scotte F, Celio L, Karthaus M, **Roeland E**. Netupitant-palonsetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice. Curr Cancer Drug Targets. 2022; 22(10): 806-824 (PMID: 35570542).
84. Winters-Stone KM, Horak F, Dieckmann NF, Luoh SW, Eckstrom E, Stoyles SA, **Roeland EJ**, Li F. GET FIT: A randomized clinical trial of tai ji qua versus strength training for fall prevention after chemotherapy in older, postmenopausal women cancer survivors. J Clin Oncol. 2023 June 20; 41(18): 3384-3396 (PMID: 36888933).
85. Anker MS, Lena A, **Roeland EJ**, Porthun J, Schmitz S, Hadzibegovic S, Sikorski P, Wilkenshoff U, Frohlich AK, Ramer LV, Rose M, Eucker J, Rassaf T, Totzeck M, Lehmann LH, von Haehling S, Coats AJS, Friede T, Butler J, Anker SD, Riess H, Landmesser U, Bullinger L, Keller U, Ahn J. Patient-reported ability to walk 4 m and to wash: new clinical endpoints and predictors of survival in patients with pre-terminal cancer. J Cachexia Sarcopenia Muscle. 2023 Aug 14 (PMID: 37222009).
86. Hadzibeogvic S, Porthun J, Lena A, Weinlander P, Luck LC, Potthoff SK, Sosnick L, Frochlich AK, Ramer LV, Sonntag F, Wilkenshoff U, Ahn J, Keller U, Bullinger L, Mahabadi AA, Totzeck M, Rassaf T, von Haehling S, Coats AJS, Anker SD, **Roeland EJ**, Landmesser U, Anker MS. Hand grip strength in patients with advanced cancer: a prospective study. J Cachexa Sarcopenia Muscle. 2023 Aug; 14(4): 1682-1694 (PMID: 37318103).
87. **Roeland EJ**, Bohlke K, Baracos VE, Smith T, Loprinzi CL. Cancer cachexia: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Sep 1; 41(25): 4178-4179 12 (PMID: 37467399).
88. Saraf Anurag, Tahir I, Hu B, Dietrich ASW, Tonnesen PE, Sharp GC, Tillman G, **Roeland EJ**, Nipp RD, Comander A, Peppercorn J, Fintelmann FJ, Jimenez RB. Sarcopenia and toxicity-related discontinuation of endocrine therapy in women with early-stage hormone-receptor-positive breast cancer. Int J Radiat Oncol Biol Phys. 2024 Jan 1; 118(1): 94-103 (PMID: 37506979).
89. Schwartzberg L, Navari RM, Ruddy KJ, LeBlanc TW, Clark-Snow R, Wickham R, Kloth D, Binder G, Bailey WL, Turini M, Potluri R, Liu X, Papademetriou E, **Roeland EJ**. Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis. Support Care Cancer. 2023 Oct 25; 31(12): 654 (PMID: 3788086).
90. **Roeland EJ**, Ruhlmann CH. 4.7.2 Management of systemic therapy toxicities. ESMO/ASCO recommendations for a global curriculum in medical oncology edition 2023. JCO Global Oncology. 2023 Sep: 9: e2300277 (PMID: 37867478, simultaneous co-publish in ESMO Open 2023).
91. Arends J, **Roeland EJ**. 4.7.3 Nutritional Support. ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023. JCO Global Oncology. 2023 4, p.27 (PMID: 37867478, simultaneous co-publish in ESMO Open 2023).
92. Winters-Stone KM, Krasnow SM, Horak FB, Mancini M, Cameron MH, Dieckmann NF, Stoyles SA, **Roeland EJ**. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538). BMC Cancer 2023 Nov 10; 23 (1): 1087 (PMID: 37946117).
93. Jarnagin JX, Saraf A, Baiev I, Chi G, vn Seventer EE, Mojtahed A, Allen JN, Clark JW, Blaszkowsky L, Giantonio BJ, Weekes CD, Klempner SJ, Franses JW, **Roeland EJ**, Goyal L, Siravegna G, Horick N, Corcoran RB, Nipp RD, Parikh AR. Patient-reported outcomes, tumor markers, and survival outcomes in advanced GI cancer. JAMA Netw Open. 2023 Nov 1;6(11): e2343512 (PMID: 37976066).
94. **Roeland EJ**, Fintelmann FJ, Halton F, Yang R, Whalen E, Tarasenko L, Calle RA, Bonomi PD. The relationship between weight gain during chemotherapy and outcomes in patients with advanced non-small cell lung cancer. J Cachexia Sarcopenia Muscle. 2024 Jun; 15(3): 1030-1040 (PMID: 38468440).
95. Braun IM, Bohlke K, Abrams DI, Anderson H, Balneaves LG, Bar-Sela G, Bowles DW, Chair PR, Damani A, Gupta A, Hallmeyer S, Subbia IM, Twelves C, Wallace MS, **Roeland EJ**. Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol 2024 May 1; 42(13): 1575-1593 (PMID: 38478773).

96. Braun IM, Bohlke K, **Roeland EJ**. Cannabis and cannabinoids in adults with cancer: ASCO guideline Q&A. JCO Oncol Pract. 2024 Jun; 20(6): 767-770 (PMID: 38478793).
97. Hjermstad MJ, Jakobsen G, Arends J, Balstad T, Brown LR, Bye A, Coats AJS, Dajani OF, Dolan RD, Fallon MT, Greil C, Grzzyb A, Kaasa S, Koteng LH, May AM, McDonald J, Ottestad I, Phillips I, **Roeland EJ**, Sayers J, Simpson MR, Skipworth RJE, Solheim TS, Sousa MS, Vagnildhaug OM, Laird BJA. Quality of life endpoints in cancer cachexia trials: systematic review 3 of the cachexia endpoints series. J Cachexia Sarcopenia Muscle. 2024 Jun; 15(3): 794-815 (PMID: 38553255).
98. Bonomi PD, Crawford J, Dunne RF, **Roeland EJ**, Smoyer KE, Siddiqui MK, McRae TD, Rossulek MI, Revkin JH, Tarasenko LC. Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: a systematic literature review and meta-analysis. J Cachexia Sarcopenia Muscle. 2024 Aug; 15(4): 1226-1239 (PMID: 38650388).
99. Winters-Stone KM, Stoyles S, Dieckmann N, Eckstrom E, Luoh SW, **Roeland EJ**, Li F. Can strength training or tai ji quan training reduce frailty in postmenopausal women treated with chemotherapy? A secondary data analysis of the GET FIT trial. J Cancer Surviv. 2024 Apr; 18(4):1179-1189 20 (PMID: 38642204).
100. Okoroma NA, Nguyen P, **Roeland EJ**, Ma JD. Evaluating the risk index for serious prescription opioid-induced respiratory depression or overdose in patients with cancer. J Pain Palliative Care Pharmacother. 2024 Jun; 38(2): 131-137 (PMID: 38722684).
101. Yule MS, Thompson J, Leesahatsawat K, Anker SD, Arends J, Balstad T, Brown L, Bye A, Dajani O, Fallon M, Hmermstad M, Jakobsen G, Laird BJA, McDonald J, McGovern J, McMillan D, **Roeland EJ**, Sayers J, Skipworth RJE, Ottestad IO, Philips I, Simpson MR, Solheim T, Sousa MS, Vagnildhaug OM, Dolan R. Biomarker endpoints in cancer cachexia clinical trials: systemic review 5 of cachexia endpoint series. J Cachexia Sarcopenia Muscle. 2024 Jun; 15(3): 853-867 (PMID: 38783477).
102. Davis MP, Davies A, McPherson ML, Reddy A, Paice JA, **Roeland E**, Walsh D, Mercadante S, Case A, Arnold R, Satomi E, Crawford G, Bruera E, Ripamonti C. Opioid analgesic dose and route conversion ratio studies: a scoping review to inform an eDelphi guideline. Support Care Cancer. 2024 Jul 24; 32(8): 542 (PMID: 39046534).
103. Groarke JD, Crawford J, Collins SM, Lubaczewski S, **Roeland EJ**, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, Dunne RF, Karahanoglu I, Northcott CA, Harrington MA, Rossulek M, Qiu R, Saxena AR. Ponsegromab for the treatment of cancer cachexia. N Engl J Med. 2024 Dec 19; 391(24): 2291-2303 (PMID: 39282907).
104. Aleem A, Sarihan C, Okhuysen PC, **Roeland EJ**, Schwartzberg L, Wang Y, Chaturvedi P. The impact of cancer-related diarrhea on changes in cancer therapy. Support Care Cancer. 2024 Sept 17; 32(10): 688 (PMID: 39287693).
105. Okoroma NA, Nguyen P, **Roeland EJ**, Ma JD. Evaluating the risk index for serious prescription opioid-induced respiratory depression or overdose in patients with cancer. J Pain Palliat Care Pharmacother. 2024 Jun; 38 (2):131-137 (PMID: 38722684).
106. Nguyen P, Okoroma NA, Ngo KK, Kaleo PK, **Roeland EJ**, Ma JD. Longitudinal evaluation of the risk index for overdose or serious opioid-induced respiratory depression in patients with cancer. J Pain Palliat Care Pharmacother. 2025 Mar; 39(1):51-57 (PMID: 39576719).
107. Davis MP, Davies A, McPherson ML, Reddy AS, Paice JA, **Roeland EJ**, Walsh D, Mercandante S, Case AA, Arnold RM, Satomi E, Crawford G, Bruera E, Bohlke K, Ripamonti C. Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline. Support Care Cancer 2025 Mar 3; 33(3): 243 (PMID: 40029420).
108. Park YH, Bianchini G, Cortes J, Licata L, Vidal M, Iihara H, **Roeland EJ**, Jordan K, Scotte F, Schwartzberg L, Navari RM, Aapro M, Rugo HS. Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncol. 2025 Apr; 21(10): 1261-1272 19:1-12 (PMID: 40105595).
109. Tung NP, Kaleo PK, **Roeland EJ**, Ma JD. Comparison of risk prediction models to estimate opioid-induced respiratory depression, oversedation, and overdose in patients with cancer. J Pain Palliat Care Pharmacother 2025 Jun; 39(2): 202-210 (PMID: 40110919).

110. Benson AE, Lo JO, Achebe MO, Aslan JS, Auerbach M, Samuelson Bannow BT, Boller MJ, Deloughery TG, Dingman J, Van Doren L, Dy GW, Ford PA, Freed JA, Gorgieff MK, Haley KM, Han CI, Kewkowtiz AK, Martens KL, Means RT, Nemeth E, Olson SR, Powers JM, Prewitt KC, Richards T, Rockey DC, **Roeland EJ**, Ryan KS, Al-Samkari H, Sholzberg M, Tuuli MG, Weyand AC, Zeller MP, Totten AM, Ivlev I, Shatzel JJ. Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations. Lancet Haematol 2025. 2025 May; 12(5): e376-e388 12 (PMID: 40306833).
111. Navari RM, Yler T, Inui N, Lihara H, Bonizzoni E, Park YH, Rugo HS, **Roeland EJ**. Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Future Oncol. 2025 Sep; 21(21): 2823-2833 (PMID: 40782019).
112. **Roeland EJ**, Fintelmann FJ, Yang R, Tarasenko L, Bonomi PD. Evaluation of weight gain and overall survival of men versus women with advanced non-small cell lung cancer. J Cachexia Sarcopenia Muscle. 2025 Dec; 16(6): e70131 (PMID: 41332393).
113. Krasnow SM, Rubin CT, **Roeland EJ**, Horak FB, Stoyles SA, Dieckmann NF, Braun KN, Winters-Stone KM. Low-intensity vibration to reduce symptoms and improve physical function in cancer survivors with chemotherapy-induced peripheral neuropathy: A pilot randomized trial. JCO Oncol Pract. 2026 Jan; 22(1): 100-111 (PMID: 40373263).
114. Molassiotis A, Jordan K, Karthaus M, Dranitsaris G, **Roeland EJ**, Schwartzberg L, Stimamiglio V, Alonzi A, Tilola SA, Bonizzoni E, Vazquez EB, Buchler T, Cheng Y, Christoph DC, Alfonso PG, Lu X, Majem M, Mavroudis D, Syrigos K, Tomlins E, Zhou Z, Zimovjanova M, Aapro M. Personalized antiemetic prophylaxis with NEPA for patients at high-risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomized, multinational, MyRisk trial. Ann Oncol. 2026 Feb; 37(2): 260-270. (PMID: 41110696).

Peer-Reviewed Abstracts (last 2 years)

1. Schwartzberg L, Okhuysen P, **Roeland E**, Vidal G, Harnden K, Zuniga R, Bosnjak S, Daggubati S, Bursac D. ONTARGET: Phase 3 randomized, double-blind, placebo-controlled trial evaluating crofelemer for the prophylaxis of diarrhea in adult patients with solid tumors receiving targeted therapies with or without standard chemotherapy. American Association for Cancer Research 2024. San Diego, CA, USA. Cancer Research 84, no. 9_Supplement (2024): PO3-13.
2. Aleem AS, Sarihan MC, Okhuysen PC, Schwartzberg L, **Roeland E**, Wang Y, Chaturvedi P. The impact of cancer-related diarrhea–a neglected comorbidity with devasting consequences. American College of Gastroenterology 2024 Annual Meeting. Philadelphia, PA, USA. Gastroenterology 166, no 5 (2024): S-958.
3. **Roeland EJ**, Crawford J, Dunne RF, Jacobs I, Groarke J, Rossulek M, Cater NB, Bonomi P. Estimating US adult cancer cachexia prevalence and impact on survival: real-world data analysis. American Society of Clinical Oncology Annual Meeting 2024 (11141). Chicago, IL, USA.
4. *Tibbitts DC, **Roeland EJ**, *Lowry SA, Moran AE, Denfeld QE, Dieckmann NF, Winters-Stone KM. Investigating sex differences in cancer immunotherapy treatment effects: the INSITE study. Abstracts from the NIH Office of Research on Women's Health 2024 Annual BIRCWH Meeting: Building Interdisciplinary Research Careers in Women's Health October 1, 2024. Journal of Women's Health, 33(9): A-1–A-30. doi: 10.1089/jwh.2024.42678.abstracts
5. Crawford J, Groarke JD, Collins SM, Lubaczewski S, **Roeland EJ**, Naito T, Hendifar AE, Fallon MT, Takayama K, Asmis TR, Dunne RF. LBA82 Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: a randomized, placebo-controlled, phase II study. European Society of Medical Oncology Annual Meeting 2024, Barcelona, Spain.
6. *Tibbitts DC, Roeland EJ, *Lowry SA, Moran AE, Denfeld QE, Dieckmann NF, Winters-Stone KM. Investigating sex and gender-related differences in immunotherapy treatment effects: the INSITE study. National Conference on Women's Health and Sex Differences Research 2024. Colorado Springs, CO, USA.
7. *Chalker C, Burton J, Kaempf A, Lim J, *Lowry S, *Beeson E, Bagwell K, Mitin T, Cetnar J, **Roeland EJ**. Gastrostomy tube (G-tube) placement timing and clinical outcomes in patients with locally advanced

squamous cell carcinoma of the head and neck receiving definitive chemoradiation. American Society of Clinical Oncology Quality Care Meeting 2024. San Francisco, CA, USA.

8. *Tibbitts DC, **Roeland EJ**, *Lowry SA, Moran AE, Denfeld QE, Dieckmann NF, Winters-Stone KM. Investigating sex and gender-related differences in immunotherapy treatment effects: the INSITE study. Poster presentation. 2024 IOTOX Symposium, Treating Immune-Related Adverse Events: Integrating Insights from Clinical, Translational, and Basic Science. Houston, TX, USA.
9. *Tibbitts DC, **Roeland EJ**, *Lowry SA, Moran AE, Denfeld QE, Dieckmann NF, Winters-Stone KM. 683 Investigating sex and gender-related differences in immunotherapy treatment effects: the INSITE study. Gerontological Society of American 2024 Annual Scientific Meeting. Seattle, WA, USA. Journal for ImmunoTherapy of Cancer 2024; 12: doi: 10.1136/jitc-2024-SITC2024.0683.
10. *Tibbitts DC, Beattie Z, **Roeland EJ**, Silbermann R, Webb JA, Meyers G, Kaye JA, Winters-Stone KM. Continuous passive monitoring of daily function and symptoms in older adults with prostate cancer. Gerontological Society of America 2024 Annual Scientific Meeting, Seattle, WA, USA.
11. Guidarelli C, Stoyles S, Dieckmann N, Sokolova A, Graff J, **Roeland E**, Winters-Stone K. Sensitivity of fall risk cutoffs using lab and remote measures on older prostate cancer survivors. Gerontological Society of America
12. Licata L, Bianchini G, Park YH, Rugo HS, Schwartzberg LS, **Roeland EJ**, Massagrande M, Dato F, Scotte F, Jordan K, Aapro MS, Iihara H. Healthcare provider (HCP) perspectives on antibody-drug conjugate (ADC)-induced nausea and vomiting: insights from an ESMO Survey. European Society of Medical Oncology Breast Cancer Annual Meeting, May 2025, Munich, Germany.
13. Lowry SA, Kaempf A, Lim JY, Chalker C, Beeson E, Abtin A, **Roeland EJ**. Exploring unmet needs in radiation-induced nausea and vomiting after moderately emetogenic treatment. American Society of Clinical Oncology Annual Meeting, June 2025, Chicago, IL, USA.
14. **Roeland EJ**, Collins SM, Estages-Wong SD, Lubaczewski SL, Naito T, Hendifar A, Fallon MT, Takayama K, Asmis TR, Dunne RF, Jacobs IA, Rossulek MI, Qiu R, Crawford J, Saxena A, Groarke J. American Society of Clinical Oncology Annual Meeting, June 2025, Chicago, IL, USA.
15. Schwartzberg LS, Licata L, Bianchini G, Park YH, **Roeland EJ**, Massagrande M, Dato F, Iihara H, Scotte F, Jordan K, Aapro MS, Rugo HS. Healthcare provider experiences in managing antibody-drug conjugate dosing adjustments due to nausea and vomiting: SABCS and ESMO survey findings. American Society of Clinical Oncology Annual Meeting, June 2025, Chicago, IL, USA.
16. **Roeland EJ**, Tejani MA, Cheung E, Dincman T, Lohiya V, Agarwal R, Sajid S, Gabayan A, Thumar JR, Jin B, Lebedinsky C, Braendle EE, Zuniga RM. American Society of Clinical Oncology Annual Meeting, June 2025, Chicago, IL, USA.

Non-Peer-Reviewed Scholarship

Editorials

1. **Roeland E**, Loprinzi C, Moynihan TJ, Smith TJ, Temel J. In: chemotherapy for lung cancer, sometimes less is more. J Natl Compr Canc Netw. 2013 March 1; 11(3): 232-5 (PMID: 23486449).
2. **Roeland E**, Leblanc T. Palliative chemotherapy: oxymoron or misunderstanding? BMC Palliative Care. 2016 Mar 21;15(1): 33 (PMID: 27000049).
3. **Roeland E**. Malignant bowel obstruction: moving beyond “drip and suck.” J Oncol Pract. 2017 Jul; 13(7): 437-438 (PMID: 28697321).
4. **Roeland EJ**. Tailoring palliative care to meet the changing needs of people with cancer. J Clin Onc. 2017 Jan 23 (PMID: 28113031).
5. **Roeland EJ**, Loprinzi CL. Reply to O. Huillard et al. J Clin Oncol 2020 Nov 10; 38(32):3819 (PMID: 32946357).
6. **Roeland EJ**, Dunne RF. The Impact of Early Referrals to Dietitians for Patients with Esophagogastric Cancer. J Natl Compr Canc Netw. 2021 Feb 2; 19(2): 235-238 (PMID: 33545687).
7. Arends J, **Roeland EJ**, Baracos VE. Important news on nutritional support in cancer patients—but some EFFORT is still ahead. Annal Oncol. 2021 July; 32(8): 953-955 (PMID: 34272040).

8. Boss RD, Creutzfeldt CJ, Fausto JA, Gonzales MJ, Grudzen CR, Hurd CJ, Kamal AH, Lam DY, Lindvall C, Melin JS, Reinke LF, **Roeland EJ**, Rosenberg AR, Sanders JJ, Smith CB, Sullivan DR, Tija J, Walling AM. Leading from the heart. J Pain Symptom Manage. 2022 Jun; 63(6): e645-e646 (PMID: 35595379).
9. Periyakoil VS, von Gunten SC, Bruera E, Currow DC, **Roeland EJ**. Symptom control research. J Palliat Med. 2022 Oct; 25(10): 1462-1467 (PMID: 7535167).
10. Winters-Stone KM, **Roeland EJ**, Li Fuzhong, Eckstrom E, Horak F, Dieckmann NF, Stoyles SA, Luoh SW. Reply to Y.-T. Hu et al. J Clin Oncol. 2023 Sep 10; 41(26): 4316-4317 (PMID: 37379504).

Chapters

1. **Roeland E**, Buckholz G. Gastrointestinal Symptoms. In: Loitman J, ed. Palliative care: case-based guide. New York, New York: Humana Press; 2010 (43-49).
2. Forner K, **Roeland E**. Palliative Care. In: Staats, Wallace, eds. Pain medicine and management: just the facts, 2nd Edition. New York, NY: McGraw Hill Education; 2015 (437-449).
3. **Roeland E**, Mitchell W, Mulroney C, Thornberry K, Atayee R, Ma J, Herman H. Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. In: Bruera, Higginson, von Gunten, Morita, eds. Textbook of Palliative Medicine and Supportive Care, 2nd Edition. Boca Raton, FL: CRC Press; 2015 (1235-1250).
4. Madlensky L**, Roeland E,** Bower K**.** Genetic counseling in the palliative care setting. In: Bruera, Higginson, von Gunten, Morita, eds. Textbook of Palliative Medicine and Supportive Care, 2nd Edition. Boca Raton, FL: CRC Press; 2015 (1283-1287).
5. Davis MP, Dalal S, Goforth HW, McPherson ML, **Roeland E**, Sloan P. UNIPAC 3: Pain assessment and management. 5th edition. Chicago, IL: American Academy of Hospice and Palliative Medicine; 2017. In: Shega JW, Paniagua M, eds., Essential Practices in Hospice and Palliative Medicine; vol 3.
6. Wang W, **Roeland E**, LeBlanc T, El-Jawahri A. Palliative Care for the Hematopoietic Cell Transplant and Cellular Therapy Clinician. In: Finn L., Roche Green AR (eds) Supportive Care Strategies. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy. Springer, 2020 (5-21).
7. **Roeland EJ**. American Society of Clinical Oncology Self Evaluation Program (ASCO-SEP), 2020. Pain and Symptom Management. ASCO-SEP 7th Edition, Alexandria, VA: ASCO, pp.179-203.
8. Kanter KN, Kestenbaum A, LeBlanc TW, **Roeland EJ**. Optimal symptom management in hematopoietic stem cell transplantation. In: Bruera, Higginson, von Gunten, Morita, eds. Textbook of Palliative Medicine and Supportive Care, 3rd Edition. CRC Press; 2021 (879-896).

Invited Lectures and Conference Presentations

International

09/15	Speaker	1. Artificial Nutrition and Hydration / Speaker 2. Early Integration of Palliative Care 3. Cancer Care at the End of Life for Hematologic Malignancies	Second International Palliative Care Conference National Autonomous University of Mexico (UNAM) Mexico City, Mexico
06/16	Speaker	Managing Nausea	National Institute of Medical Sciences and Nutrition Salvador Zubrián National Autonomous University of Mexico (UNAM) Mexico City, Mexico

06/17	Speaker	1. Medical Cannabis 2. Use of Olanzapine for Nausea and Vomiting in Palliative Care	International Pain and Palliative Medicine Forum National Institute of Medical Sciences and Nutrition Salvador Zubrián National Autonomous University of Mexico (UNAM) Mexico City, Mexico
06/17	Plenary Speaker	Cancer Cachexia	13th Chinese National Congress on Cancer Rehabilitation and Palliative Care Hefei, Anhui Province, China
09/18	Speaker	1. Liver disease 2. Neurologic diseases	Global Studies Seminar Clinical Criteria for Non-Cancer Terminal Conditions National Autonomous University of Mexico (UNAM) Mexico City, Mexico
09/18	Speaker	Palliative Care Grand Rounds & Discussion of Challenging Cases	Dr. Manuel Gea González General Hospital Mexico City, Mexico
09/20	Speaker	The "Skinny" on the Inaugural ASCO Cancer Cachexia Guidelines	Virtual Cancer Cachexia Conference 2020 Virtual presentation in the COVID-19 Era
09/20	Speaker	Review of the ASCO Cancer Cachexia Guidelines	International Pain and Palliative Medicine Forum National Institute of Medical Sciences and Nutrition Salvador Zubrián National Autonomous University of Mexico (UNAM) Virtual presentation in the COVID-19 Era
12/21	Co-Chair	Progress in Therapeutics	Society of Sarcopenia, Cachexia, and Wasting Disorders 14th International Conference on Cachexia, Sarcopenia, and Muscle Wasting Virtual presentation in the COVID-19 Era
06/22	Speaker	Designing Trials for Cancer Cachexia – Selecting Populations	Society of Sarcopenia, Cachexia, Wasting Disorders 15th International Conference on Cachexia, Sarcopenia, and Muscle Wasting Lisbon School of Medicine, Lisbon, Portugal
09/22	Speaker	Evaluation of Weight Gain and Overall Survival of Male vs. Female Patients with Advanced Non-Small Cell Lung Cancer Receiving First-line Chemotherapy	European Society of Medical Oncology Proffered Paper Session: Supportive and Palliative Care Paris, France
04/24	Speaker	Rapid Update to the ASCO Cancer Cachexia Guidelines	CRUK/NCI Cancer Grand Challenges Team CANCAN Virtual Seminar Series Virtual presentation
06/24	Speaker	1. Cannabis and Cannabinoids in Adults with Cancer: ASCO Guideline 2. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update	XV International Pain and Palliative Medicine Forum National Institute of Medical Sciences and Nutrition Salvador Zubrián National Autonomous University of Mexico (UNAM) Mexico City, Mexico

9/25	Speaker	1. Session: Current Management of Cancer Cachexia Current Clinical Management of Cancer Cachexia 2. Session: Clinical Trials Updates RIVER-PDAC: A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab Compared with Placebo Both with Background First-Line Chemotherapy in Adult Participants with Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma (NCT06989437)	Cancer Cachexia Society 2025 Conference Universita degli Studi di Torino (UNITO) Turin, Italy

National

05/13	Speaker	Managing Acute-on-Chronic Pain in the Hospitalized Patient	Society of Hospital Medicine Annual Meeting Washington DC
03/14	Speaker	I Feel Your Pain: Managing Acute Pain in the Chronic Pain Patient	Society of Hospital Medicine Annual Meeting Las Vegas, NV
02/15	Speaker	Polypharmacy Police vs. Patient Advocate: An Evidence-Based, Patient-Tailored Approach to Medication Simplification Strategies for Palliative Care	American Academy of Hospice and Palliative Medicine Annual Meeting Philadelphia, PA
09/15	Speaker	Cancer Cachexia and Assessing Quality of Life	Global Palliative Care Quality Alliance Webinar
09/15	Speaker	Current and Emerging Therapies for the Treatment of Cancer Cachexia	American College of Clinical Pharmacy Annual Meeting San Francisco, CA
12/15	Speaker	Spanning the Canyon Between Stem Cell Transplantation and Palliative Care	American Society of Hematology Annual Meeting Education Program Orlando, FL
03/16	Speaker	The Good, The Bad, and The Ugly: Pain Management for the Hospitalist	Society of Hospital Medicine Annual Meeting San Diego, CA

05/16	Plenary Speaker	Optimizing Quality of Life in Patients with Advanced Cancer	American Urology Association Annual Meeting San Diego, CA
06/16	Discussant	Breaking Bad Symptoms	American Society of Clinical Oncology Annual Meeting Patient and Survivor Care Track Chicago, IL
09/16	Speaker	Palliative Care in Marrow and Stem Cell Transplant	Association of Veterans Administration Hematology/Oncology (AVAHO) Dallas, TX
11/16	Speaker	Palliative Care in Stem Cell Transplantation	Kaiser Permanente Hematology/Oncology Portland, OR
03/17	Speaker	Patient-Reported Outcomes: Clinical and Practical Considerations	Pfizer Inc La Jolla, CA
08/17	Speaker	Olanzapine in the Treatment of Chronic Nausea	University of Alabama at Birmingham Division of Gerontology, Geriatrics, and Palliative Care Grand Rounds Birmingham, AL
10/17	Speaker	Integrating Hematologic Malignancies and Palliative Care: Ready for Primetime?	Global Palliative Care Quality Alliance Webinar
10/17	Session Chair	Symptom Management	American Society of Clinical Oncology Palliative and Supportive Care Symposium San Diego, CA
10/17	Speaker	Prognostication in the Immunotherapy Era	American Society of Clinical Oncology Palliative and Supportive Care Symposium San Diego, CA
11/17	Speaker	Integration of Palliative Care into the Care of Stem Cell Transplant Patients	National Marrow Donor Program Council Meeting Minneapolis, MN
12/17	Panelist, Discussant, and Speaker	Multidisciplinary Approach to Diarrhea Prevention and Management in the Cancer Patient	Food and Drug Administration Bethesda, MD
02/18	Panelist	1. Managing Stress, Anxiety, and Depression in My Patients 2. The Role of Palliative Care in Improving Health-Related Quality of Life	United States Cutaneous Lymphoma Consortium San Diego, CA
03/18	Speaker	Healthy Volunteers in Phase I Oncology Clinical Trials: Through the Patient Lens	American Society of Bone Marrow Transplant Annual Meeting Orlando, FL

07/18	Speaker	Patient and Survivor Care	American Society of Clinical Oncology Best of ASCO Annual Meeting San Diego, CA
11/18	Speaker	Palliative Care: How to Make the Best of the Worst	4th Annual West Cancer Center Oncology Conference Memphis, TN
11/18	Chair	The Great Opioid Debate	American Society of Clinical Oncology Palliative and Supportive Care Symposium San Diego, CA
11/18	Speaker	Opioid Challenges for Cancer Patients in Today's Push for Reduction	Sharp Healthcare Possibilities, Probabilities, and Prediction: Practical Strategies to Use for Supportive and Palliative Care in Oncology San Diego, CA
05/19	Chair	Seeking Balance in Opioid Prescribing	American Society of Clinical Oncology Annual Meeting Chicago, IL
10/19	Chair	Keynote Lecture	American Society of Clinical Oncology Supportive Care Symposium San Francisco, CA
10/19	Panel Discussant	Optimal Use of Corticosteroids in Palliative Oncology	American Society of Clinical Oncology Supportive Care Symposium San Francisco, CA
05/20	Discussant	Breaking Bad: Evaluating Efficacy of Old and New Drugs on Symptom Management	American Society of Clinical Oncology Annual Meeting Virtual presentation in the COVID-19 Era
09/20	Speaker	The "Skinny" on Cancer Cachexia	Grand Rounds Indiana University Melvin & Bren Simon Comprehensive Cancer Center Virtual presentation during the COVID-19 pandemic
11/20	Speaker	Clinical Trial in Cancer Cachexia – Knowing the Past to Shape the Future	Cancer Cachexia Society Seminar Series Virtual presentation during the COVID-19 pandemic
04/20	Speaker and Panel Discussant	Cancer Cachexia Mini-Symposium	Food and Drug Administration Virtual presentation during the COVID-19 pandemic
08/20	Panel Discussant	Conversations with Patients and Caregivers	6th Cancer Cachexia Conference Virtual presentation during the COVID-19 pandemic
04/23	Speaker	Cachexia, Sarcopenia, and Frailty: Different Perspectives of a Similar Challenge?	University of Oklahoma Health Sciences Center 2023 Nathan Shock Center Geroscience Symposium The Intersection of Sarcopenia in Aging and Cancer Cachexia Oklahoma City, OK
06/24	Chair	Multidisciplinary Approach to Navigating Early-Stage Rectal Cancer	American Society of Clinical Oncology Annual Meeting Case-Based Panel Discussion Chicago, IL

07/24	Speaker	Symptom Science and Palliative Care	American Society of Clinical Oncology Best of ASCO Boston, MA
09/24	Discussant	Oral Abstract Session A	American Society of Clinical Oncology Quality Care Symposium San Francisco, CA
10/24	Speaker	ASCO Cannabis Guideline: Summarizing the Evidence to Inform Policy, Practice, and Next Steps	Memorial Sloan Kettering Cancer Center Department of Epidemiology and Biostatistics Health Outcomes Research Group New York, NY
11/24	Speaker	Mentorship at the Intersection of Medical Oncology and Palliative Care	American Society of Clinical Oncology Palliative Care Community of Practice Virtual interactive presentation
12/24	Speaker	What is the Standard of Care for Patients with Cancer Cachexia?	Sarcopenia Cachexia Wasting Disorders Annual Conference Regulatory Workshop Washington, DC
04/25	Speaker	Cancer Cachexia: from Preclinical Models to Bedside Interventions	National Cancer Institute Division of Cancer Prevention Building Bridges Symptom Science Webinar
05/25	Chair	"What About Cannabis?": Incorporating Evidence to Facilitate Informed Discussions with Patients and Caregivers	American Society of Clinical Oncology Annual Meeting Case-Based Discussion Chicago, IL
05/25	Speaker	Future Educational Content at ASCO – Developing Themes & Objectives	American Society of Clinical Oncology Inaugural ASPIRE Community of Practice Meeting Chicago, IL
05/25	Speaker	Mentorship at the Intersection of Oncology and Palliative Care	American Society of Clinical Oncology Palliative Care Community of Practice Meeting Chicago, IL
06/25	Discussant	ASCO 2025 Abstract Discussant Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiation-induced nausea and vomiting: CTRI/2022/01/039723	American Cancer Society / Center to Advance Palliative Care Strengthening Palliative Care in Oncology Virtual Webinar
06/25	Speaker	Workshop: Partnering with patients in managing chronic toxicities of cancer and its treatment Long-term side effects of existing and emerging modalities	Multinational Association for Supportive Care in Cancer Annual Meeting Seattle, WA
06/25	Chair	Plenary: Emerging toxicities of emerging treatments	Multinational Association for Supportive Care in Cancer Annual Meeting Seattle, WA

06/25	Speaker	Psychedelics and cannabis anyone? Opportunities and challenges of drug repurposing in the management of emerging psychosocial challenges Cannabis and cannabinoids in supportive care for cancer	Multinational Association for Supportive Care in Cancer Annual Meeting Seattle, WA
01/26	Speaker	The hidden burden: why cachexia matters	American Society of Clinical Oncology Gastrointestinal Cancers Symposium Collaborative Oncology Alliance for Cachexia Education (COACH-ED) CME Program San Francisco, CA

Regional

12/08	Speaker	Darkness No More "Light Up a Life" Annual Fundraiser	San Diego Hospice and the Institute for Palliative Medicine San Diego, CA
04/12	Speaker	Initiating a Palliative Care Program at an Academic Tertiary Care Center	University of California Los Angeles Los Angeles, CA
09/14	Speaker	Redefining the Role of Paternalism in Palliative Medicine Grand Rounds	City of Hope Grand Rounds Duarte, CA
07/15	Speaker	Cancer Symptom Management and Clinical Research	San Diego Professional Oncology Network San Diego, CA
11/24	Speaker	Cannabis and Cannabinoids in the Care of People Living with Cancer: Applying the Evidence to Clinic, Policy, and Advocacy	Oregon Health and Science University All City Palliative Care Lecture Series Portland, OR
11/24	Speaker	Immune Checkpoint Inhibitors: Essential Insights for the Practicing Internist	American College of Physicians Oregon Chapter Annual Meeting Portland, OR
11/24	Speaker	Ponsegromab for the Treatment of Cancer Cachexia	Portland's Medical Oncology Journal Club Portland, OR
11/24	Discussant	Ponsegromab for the Treatment of Cancer Cachexia	University of California San Diego Moores Cancer Center Hematology-Oncology Fellowship Series Virtual presentation with Dr. Karen Resnick

Local/Institutional

11/14	Speaker	Pulmonary and Critical Care Grand Rounds	University of California San Diego La Jolla, CA

09/15	Speaker	Optimal Symptom Management	Pseudomyxoma Peritonei Cancer Symposium La Jolla, CA
09/16	Speaker	1. Palliative Care: Optimal Symptom Management to Advance Care Planning 2. Palliative vs. Hospice Care	San Diego State University / University of California San Diego U54 Partnership Annual Retreat La Jolla, CA
08/21	Speaker	Cancer Cachexia: Clinical Trial Considerations	Oregon Health and Science University Pediatric and Adult Palliative Care Grand Rounds Portland, OR
04/22	Speaker	What the Heck is Symptom Science?	Oregon Health and Science University Knight Cancer Center Clinical Research Management and Clinical Research Quality & Administration monthly seminar series Portland, OR
10/22	Speaker	The Role of Palliative Care in Sarcoma	Oregon Health and Science University Knight Cancer Institute Sarcoma Patient Education Conference 2022 Portland, OR
12/22	Panelist	Patient Resiliency: Symptom Science Q&A and Strategic Planning Discussion	Oregon Health and Science University Knight Cancer Institute Brenden-Colon Center for Pancreatic Cancer 2022 Scientific Retreat Portland, OR
04/25	Speaker	Symptom Science: Optimizing the Patient Experience in Cancer Care	Oregon Health and Science University Knight Cancer Institute Biostatistics Shared Resource Cancer Clinical Trials Methods: Training and Workshop Portland, OR
04/25	Speaker	Building Study Protocol Observations: Patient-Reported Outcomes	Oregon Health and Science University Knight Cancer Institute Investigator-Initiated Trial Incubator Portland, OR
11/25	Speaker	Branden-Colson Center for Pancreatic Care Pancreatic Cancer Thrivership Community Conference	Supportive Care & Cachexia Knight Cancer Institute Portland, OR
01/26	Speaker	26th Annual Hematology and Breast Cancer Update	Immune Checkpoint Inhibitor Toxicities: Essential Insights for the Practicing Clinician Knight Cancer Institute Portland, OR

Honors and Awards

2009	Dickinson Foundation Palliative Medicine Fellow	San Diego Hospice and The Institute of Palliative Medicine	Endowed palliative care fellow scholar

2011	Travel Scholar	American Society of Clinical Oncology	Clinical research award to attend the annual meeting
2013	National Center of Leadership in Academic Medicine	University of California San Diego	Junior faculty leadership training program
2014	Kathleen Foley Palliative Care Research Scholars Award	American Academy of Hospice and Palliative Medicine	Research scholar award in recognition of research contribution and participation
2015	Inspirational Leader Under 40 Award	American Academy of Hospice and Palliative Medicine	Award for contribution and leadership in palliative care
2015	Fellow of the American Academy of Hospice and Palliative Medicine (FAAHPM)	American Academy of Hospice and Palliative Medicine	Distinction for members with a dedicated track record of volunteering for AAHPM
2015	Top Hospice and Palliative Medicine Physician	San Diego Journal	San Diego's Top Doctors
2017, 2018	Supportive Oncology Workshop	Massachusetts General Hospital	Selected small group co-leader alum faculty
2019, 2021	Brian A. McGovern, MD Award for Clinical Excellence Award Nominee	Massachusetts General Physicians Organization	Faculty nomination for commitment to physician skill, caring, and compassion
2020	Top Oncology Internal Medicine Educator Nominee	Massachusetts General Hospital	End-of-the-year internal medicine residency survey for faculty committed to teaching house staff
2023	Fellow of the American Society of Clinical Oncology (FASCO)	American Society of Clinical Oncology	Distinction for members with a dedicated track record of volunteering for ASCO, Conquer Cancer, and its Foundation
2024	Continuing Professional Development Clinical Star Award	Oregon Health and Science University	Recognition for exemplary patient experience scores in the top quartile of all OHSU clinicians
2024	Notable Articles of the Year	New England Journal of Medicine	*The NEJM Editors selected Ponsegromab for the Treatment of Cancer Cachexia* as one of the year's most notable and impactful articles in 2024.
2025	Outstanding Mentor Award	Oregon Health and Science University	OHSU School of Medicine Recognition for dedication, contribution, and impact supporting faculty.

VII. SERVICE

Clinical Responsibilities

2012 - 2018	Ambulatory Care	Gastrointestinal Cancer UC San Diego Moores Cancer Center San Diego, CA, USA	6 hours per week
2012 - 2018	Ambulatory Care	Palliative Care UC San Diego Moores Cancer Center San Diego, CA, USA	12 hours per week
2012 - 2018	Inpatient Care	Medical Oncology UC San Diego Moores Cancer Center San Diego, CA, USA	6 weeks per year
2018 - 2021	Ambulatory Care	Gastrointestinal Oncology Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital, Boston, MA, USA	8 hours per week
2018 - 2021	Ambulatory Care	Gastrointestinal Oncology MGH Newton-Wellesley Hospital Newton, MA, USA	8 hours per week
2018 - 2021	Inpatient Care	Medical Oncology Massachusetts General Hospital Boston, MA, USA	6 weeks per year
2021 - 2022	Ambulatory Care	Cutaneous Oncology Oregon Health and Science University, Portland, OR, USA	16 hours per week
2021 -	Inpatient Care	Medical Oncology Consult Service Oregon Health and Science University, Portland, OR, USA	3-4 weeks per year
2022 - 2025	Ambulatory Care	Symptom Science and Palliative Care Oregon Health and Science University, Portland, OR, USA	16 hours per week
2025 -	Ambulatory Care	Cutaneous Oncology Oregon Health and Science University, Portland, OR, USA	16 hours per week

Granting Agency Review Work

2014 - 2019	Palliative Care Research Cooperative Scientific Review Committee	Reviewer
2019	Republic of Ireland Health Research Board Emerging Investigator Award	Reviewer
2022, 2023	Worldwide Cancer Research	Reviewer

	Yorkshire Cancer Research Sheffield Pioneers Fund	
2022	Oregon Health and Science University Knight Cancer Institute FY23 Cancer Prevention and Control Pilot Awards	Reviewer
2024	Alliance for Clinical Trials in Oncology Cancer Control Program Pilot Project Eliminating Inequities and Delivering Optimal Care	Reviewer

Thesis Examinations

2024	Pamela Klassen, PhD, RD Nutrition & Metabolism *Enhancing nutrition care in advanced pancreatic cancer: defining clinical contributors to malnutrition progression and the impact of pancreatic enzyme replacement therapy*	University of Alberta Edmonton, Alberta, Canada Department of Oncology	Invited External Examiner
2025	Jonas Sørensen, MBBS, PhD Molecular Metabolism *Bridging molecular and patient-centered research in cancer cachexia*	University of Copenhagen Copenhagen, Denmark Department of Biomedical Sciences	Invited External Examiner

Editorial

2012 - 2018	Journal of Community and Supportive Oncology	Member Editorial Advisory Board
2016 - 2020	Journal of Palliative Care	Associate Editor
2020 - 2024	Ullrich, Christina K., and Eric J. Roeland, eds. Palliative Care in Hematologic Malignancies and Serious Blood Disorders: A Clinical Guide. Springer Nature, 2024 eBook ISBN 978-3-031-38058-7 | Print ISBN 978-3-031-38057-0	Co-Editor
2020 - 2022	Department of Health and Human Services Agency for Healthcare Research and Quality (AHRQ) 1. Interventions for Breathlessness in Patients with Advanced Cancer (PMID: 33289989) 2. Radiation Therapy for Bone Metastases (PMID:37851844) 3. Nutrition as Prevention for Improved Cancer Health Outcomes (PMID: 37289928)	Peer reviewer, technical expert
2021 - 2023	Supportive Care in Cancer	Associate Editor
2023 - 2025	New England Journal of Medicine Knowledge Plus (NEJM+) Pain Management and Opioids	Section Editor

2025 -	UpToDate Symptom Science and Palliative Care	Section Editor

Ad Hoc Reviewer

Journal	*Impact Factor* (01/25)
Nature Medicine	55.0
Annals of Oncology	51.77
Journal of Clinical Oncology	45.3
British Medical Journal	43.0
European Heart Journal	39.3
JAMA Oncology	33.01
JAMA Network Open	13.353
Molecular Therapy	12.910
Journal of the National Comprehensive Cancer Network: JNCCN	12.693
Journal of Cachexia, Sarcopenia and Muscle	12.063
Journal of Immunotherapy of Cancer	10.900
International Journal of Radiation Oncology	8.013
Cancer	6.921
The Oncologist	5.837
Journal of Clinical Medicine	4.964
BMC Oncology	4.638
Annals of Surgical Oncology	4.339
British Journal of Nutrition	4.125
Journal of Geriatric Oncology	3.929
PLOS	3.700
Supportive Care in Cancer	3.603
Psycho-Oncology	3.600
JCO Journal of Oncology Practice	4.7
BMC Cancer	3.500
Journal of Pain and Symptom Management	3.077
Leukemia and Lymphoma	2.996
Journal of Palliative Medicine	2.947
Cancer Medicine	2.872
Journal of Medical Internet Research Cancer	2.800
BMC Surgery	2.030
European Journal of Cancer Care	2.020
Pain Management	1.700

Clinical Nutrition Open Science	0.411
Journal of Opioid Management	0.311

Committee and Professional Association Service

International

2012 -	Multinational Association of Supportive Care in Cancer		
	2018 - 2019	Annual Assembly Local Organizing Committee	Member
	2024 - 2025	Annual Assembly Local Organizing Committee	Member
2020 -	Cancer Cachexia Society		Member

National

2008 -	American Academy of Hospice and Palliative Medicine (AAHPM)		
	2015 - 2017	Industry Relations Task Force	Chair
	2015 - 2017	Research Committee	Member, Reviewer
	2016 - 2019	Cancer Special Interest Group	Chair
	2017 - 2019	Annual Assembly Program Planning Committee	Member
	2018 - 2021	State of the Science in Hospice and Palliative Medicine Program Committee	Member
2009 -	American Society of Clinical Oncology (ASCO)		
	2015 - 2017	Supportive Care Guidelines	Member
	2015 - 2018	Palliative Care and Supportive Care in Oncology Symposium Program Planning Committee	Member
	2018	ASCO University Online CME Course Cancer Pain Basics – Pain Management	Educator
	2018 - 2021	Supportive Care Guidelines	Co-Chair
	2019	Supportive Care in Oncology Symposium Planning Committee	Co-Chair
	2019 -	Cancer Cachexia Guidelines	Co-Chair, First Author
	2019 -	International Education Steering Committee	Member
	2020 - 2021	Management of Dyspnea in Advanced Cancer Guideline Committee	Member, Co-Author
	2021 - 2026	Evidence-Based Medicine Committee (EBMC) Guidelines	Chair (2025-2026), Member

	2021	Genomic Testing in Patients with Metastatic/Advanced Cancer: ASCO Provisional Clinical Opinion (PMID: 35175857)	EBMC Reviewer
	2022	Use of Opioids for Adults with Pain from Cancer or Cancer Treatment: ASCO Guideline (PMID: 36469839)	EBMC Reviewer
	2023 -	Methodologies Subcommittee	Member
	2024	Vaccination of Adults with Cancer: ASCO Guideline (PMID: 38498792)	EBMC Reviewer
	2024	Palliative Care for Patients with Cancer: ASCO Guideline Update (PMID: 38748941)	EBMC Reviewer
	2022 -	Medical Cannabis in Patients with Cancer	Co-Chair, Senior Author
	2023 - 2026	Annual Meeting Scientific Program Committee Symptom Science and Palliative Care Track	Track Leader, Member
	2024 -	Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy Guideline	Member, Co-Author
	2025 -	Alliance for Support and Prevention of Immune-Related Adverse Events (ASPIRE) Community of Practice	Founding Co-Champion
2011 - 2013	National Cancer Institute		
	2011 - 2013	Symptom Management and Quality of Life Drug Development Task Force	Member
2011 -	Alliance for Clinical Trials in Oncology		
	2011 - 2020	Symptom Intervention Committee	Member
	2021 -	Symptom Intervention Committee	Vice Chair
2013 - 2021	National Comprehensive Cancer Network		
	2013 - 2018	Adult Cancer Pain Panel	Member, Reviewer
	2013 - 2021	Antiemesis Panel	Member, Reviewer
2014 - 2020	Palliative Care Research Collaborative		
	2014 - 2020	Scientific Review Committee	Member, Reviewer
	2018 - 2020	Industry Relations Task Force	Chair
2015 - 2020	American Society for Transplantation and Cellular Therapy		
	2015 - 2020	Palliative Care Task Force	Member, Investigator
2018 - 2020	Palliative Care Quality Network		
	2015 - 2020	Research and Development Working Group	Member

2019 -	Agency for Healthcare Research and Quality		
	2019 -	Supportive Care Guideline Reviewer	Technical expert
2021 - 2024	Pancreatic Cancer Action Network		
	2021 - 2024	Precision Promise Supportive Care Committee	Member
2024	Association of Cancer Care Centers (ACCC)		
	2024	Immuno-Oncology Institute Program Remote Patient Monitoring Effective Practice Guide for Immune-Related Adverse Events (irAEs)	Advisor
2024 -	Alliance for Support and Prevention of Immune-Related Events (ASPIRE)		
	2024 -	Executive Committee	Member

Local/Institutional

2006 - 2018	University of California San Diego		
	2006 - 2012	Medical Ethics Committee	Member, Consultant
	2011 - 2012	Graduate Medical Education Committee	Fellow Representative
	2011 - 2018	Internal Medicine Residency Program Selection Committee	Member, Interviewer
2012 - 2018	University of California San Diego, Moores Cancer Center		
	2012 - 2014	Scientific Protocol Review Monitoring Committee	Member, Reviewer
	2012 - 2013	Patient Experience Committee	Member
	2014 - 2017	Institutional Review Board, Oncology Committee	Member, Reviewer
	2015 - 2017	Charity Care Committee	Member, Reviewer
2020 - 2021	Dana Farber / Harvard Cancer Center		
	2020 - 2021	Scientific Review Committee / Institutional Review Board	Member, Reviewer
2022 -	Oregon Health and Science University, Knight Cancer Institute		
	2022 -	Oncology Informatics Working Group	Member
	2023	Search Committee for Associate Director of Population Science	Member
	2024 -	Department of Medicine Promotion and Tenure Committee	Member
	2024 -	Knight Cancer Institute Clinical Research Committee	Member
	2024 -	Research Oversight Subcommittee	Member

Community Engagement/Outreach

Events

2014, 2015	Pedal the Cause University of California San Diego Moores Cancer Center Team "From Start to Finish" San Diego, CA, USA	Team Leader, Participant
2022	Pancreatic Cancer Action Network Purple Stride Event, OHSU Team San Diego, CA, USA	Participant
2023	Collaborative Ocular Oncology Group Advisory Meeting American Society of Clinical Oncology Annual Meeting Chicago, IL, USA	Patient Advocate
2024	Collaborative Ocular Oncology Group Advisory Meeting American Society of Clinical Oncology Annual Meeting Chicago, IL, USA	Patient Advocate
2024	Cure Ocular Melanoma Global Science Meeting Melanoma Research Foundation Annual Meeting New Orleans, LA, USA	Patient Advocate

Patient and Community Lectures

03/13	Choosing life or a better death: hospice under scrutiny	KBPS San Diego
03/15	How San Diego cancer treatments are creating new survivors	KPBS San Diego
03/16, 11/14	Optimizing your quality of life during cancer treatment Webinar	Pancreatic Cancer Action Network
2017	Doctors want to give their cancer patients every chance, but are they pushing off hard talks for too long?	Stat News
11/19	1. Cancer diagnosis 2. Optimizing quality of life	ASCO Connection
04/20	Living with cancer: fostering community and combating loneliness Survivorship webinar Virtual presentation during the COVID-19 pandemic	Neshama: Association of Jewish Chaplains Annual Meeting
10/20	Current treatment approaches and existing guidelines: cancer cachexia interventions Unmet needs from the patient's perspective multi-stakeholder workshop Virtual presentation during the COVID-19 pandemic	Lungevity Action Network

06/20	Dealing with cancer-related fatigue Patient educational series Virtual presentation during the COVID-19 pandemic	National Chordoma Foundation
06/20	Survivorship: the certainly uncertain adventure Patient survivorship lecture series Virtual presentation during the COVID-19 pandemic	Massachusetts General Hospital Newton-Wellesley

Media

2015	Quality of life and satisfaction with care	ASCO Post.com
2015	Palliative care for patients with hematologic malignancies	ASCO Post.com
2015	The importance of proactive CINV management	OncLive
2015	Tips for treating pain in hospitalized patients	Medscape
2015	Toward better treatment for cachexia	ASCO Post.com
2015	Palliative and supportive care	The Conversation, Lung Ed
2015	The beginning, not the end	ASH Daily News
2015	Top takeaways from ASH: palliative care emerges in treatment for hematologic malignancies	HemOnc Today
2016	Morphine more effective than weak opioids for cancer pain	HemOnc Today
2016	Integrative palliative and oncology care	ASCO Post.com
2016	Gynecological cancer and managing symptoms	ASCO Post.com
2016	Debate on physician-assisted death	ASCO Post.com
2016	Expert perspective on palliative care in oncology meeting highlights	ASCO Post.com
2016	Palliative care in hematologic malignancies: focus on needs, not prognosis	AAHPM Quarterly
2017	Challenges in the treatment of CINV	OncLive
2017	Effective palliative care engagement in the era of immunotherapy	AAHPM Quarterly
2017	CINV packs an economic and emotional impact on patients	Cure Today
2018	The challenge of prognostication in the era of immunotherapy	ASCO Post
2018	Eric Roeland, MD, on preventing chemotherapy-induced vomiting	ASCO Post
2019	Reducing cancer patients' risk of opioid addiction, harm	MedPage Today
2020	Q&A: Minimizing chemotherapy-related nausea and vomiting	Cancer Today
2022	Facing unintended appetite and weight loss during colorectal cancer?	F!ght Colorectal Cancer

2022	Cancer cachexia: after years of no advances, progress looks possible	National Cancer Institute
2022	Is cannabis a solution for breast cancer patients' chemo side effects?	The Columbian
2023	ASCO releases rapid recommendation update on the use of olanzapine to treat cancer-related cachexia	The ASCO Post
2024	Is it safe to use cannabis and cannabinoids during cancer?	Cancer.Net
2024	'Symptom science' aims to ease burden of cancer treatment	News.OHSU.edu
2024	ASCO guideline helps clinicians address cannabis use 'head on' with their patients	Helio.com
2024	'Symptom science' research effort aims to optimize quality of life, minimize toxicities	Helio.com
2024	New therapy shows promise in improving appetite, quality of life for patients living with cancer	OHSU News
2024	New OHSU study shows promise in treating 'urgent, unmet need' in cancer patients	Yahoo! News KOIN CBS News
2024	Positive trial of ponsegromab may signal 'start of a revolution' for cancer cachexia	Helio.com
2025	Cancer and fatigue: symptom or sign?	Checkpoint NOW podcast
2025	ASCO and Google create 'walled garden' AI tool for doctors to query group's guidelines	STAT
2025	Low iron is common, but fixable. Here's how to boost your levels naturally	BBC
2025	Maybe it's not just aging. Maybe it's anemia.	New York Times

Quality, Systems Improvement, and Patient Safety

2016 American Society of Clinical Oncology (ASCO)
Pilot Pain Survey Quality Improvement Project
Site Principal Investigator (In-kind)
Two sites were selected to participate in a quality improvement project to determine if an opioid safety questionnaire delivered in an outpatient palliative care clinic was feasible and improved communication surrounding opioids. Our participation shaped ASCO education efforts, recommendations for ASCO membership to improve opioid safety in outpatient oncology clinics, and informed patient educational materials. Results were presented at the 2017 ASCO Quality Care Symposium, and materials are now available to all ASCO members.

VIII. TEACHING

Direct Teaching Activities

Year(s)	*Role*	*Course Details*	*Level of activity*
2011 - 2016	Facilitator	University of California San Diego School of Medicine (SOM 231) Principals of Clinical Oncology Problem-based learning groups	4 hours per year
2012 - 2018	Educator	University of California San Diego Palliative Care Fellow Core Lecture Series Oncology Topics for the Palliative Care Clinician	4 hours per year
2012 - 2018	Educator	University of California San Diego Hematology/Oncology Fellow Core Lecture Series Palliative Care Topics for the Oncologist	2 hours per year
2014 - 2018	Discussant	University of California San Diego Skaggs School of Pharmacy SPPS 273/BIOM267/PHARM210/MGT317250 Drug Discovery, Development, and Commercialization	1 hour per year
2016	Facilitator	University of California San Diego School of Medicine Clerkship Proctored Patient Interview	10 hours per year
2019 - 2020	Educator	Massachusetts General Hospital Hematology/Oncology Fellow Core Weekly Lecture Series Symptom Management Chalk Talk	2 hours per year
2020 - 2021	Educator	Massachusetts General Hospital Internal Medicine Core Lunch Lecture Series Symptom Management Chalk Talk	2 hours per year
2021 -	Educator	Oregon Health and Science University Hematology/Oncology Fellow Core Weekly Lecture Series Symptom Management	4 hours per year
2021 -	Educator	Oregon Health and Science University Palliative Care Fellow Core Weekly Lecture Series Symptom Management	2 hours per year

Clinical Teaching Activities

2012 - 2018	Ambulatory Care Clinical Supervisor	University of California San Diego Moores Cancer Center	Medical and pharmacy students, internal

		Palliative Care La Jolla, CA	medicine residents, palliative care fellows, gynecology oncology fellows, pain anesthesia fellows
2012 - 2018	Inpatient Care	University of California San Diego Medical Oncology La Jolla, CA	Medical and pharmacy students, internal medicine residents, hematology/oncology fellows
2018 - 2021	Ambulatory Care	Massachusetts General Hospital Tucker Gosnell Center for Gastrointestinal Cancers Boston, MA	Hematology/oncology fellows
2018 - 2021	Inpatient Care	Massachusetts General Hospital Medical Oncology Ellison 16 Boston, MA	Internal medicine residents
2021 -	Inpatient Care	Oregon Health and Science University Medical Oncology Consult Service Portland, OR	Hematology/oncology fellows, internal medicine residents

Curriculum Development

2012 - 2014	Co-Chair	University of California San Diego Skaggs School of Pharmacy (SPPS 269) Pharmacotherapy of Pain Management	24 hours per year
	Purpose/Need:	The purpose of this course was to engage learners regarding evidence-based strategies for symptom management, including a focus on clinically relevant pearls and a 3-hour clinical observation.	
	Intended Audience:	School of Pharmacy Students	
	Duration:	9 weeks of lecture, 2 hours per week, plus a one-time on-site visit in a pain management setting (3 hours)	
	Methods/Design:	Didactic (2 hours) case-based problem solving focusing on clinical pearls each week and one-time on-site visit in a pain management setting (3 hours)	
	Significant Results & Outcomes:	This elective course was highly rated by students and consistently received excellent reviews	
	Dissemination:	Handouts for the core lectures were shared with the UC San Diego pharmacy residents and were available as references during clinical rotations	

Lectures

<u>International</u>

Date	*Role*	*Topics*	*Program*
05/09	Educator	1. Managing Anxiety 2. Treating Depression	San Diego Hospice and the Institute for Palliative Medicine Slovenia Palliative Medicine Palliative Care Development Institute Ljubljana Golnik, Slovenia
04/21	Facilitator, Model with Simulated Patient	1. Pathophysiology and Management of Bone, Abdominal, and Neuropathic Pain 2. Loss, Compassion Fatigue, Burnout, and Resilience 3. Difficult Decision-Making: Fluids and Nutrition, Antibiotics	American Society of Clinical Oncology International Palliative Care Interdisciplinary Curriculum TaTa Memorial Hospital e-Course Mumbai, India
06/24	Facilitator	Communicating Prognosis Effectively	American Society of Clinical Oncology International Palliative Care e-Course Indonesia

<u>National</u>

Date	*Role*	*Topics*	*Program*
08/17	Educator	Palliative Care and Survivorship	American Society of Clinical Oncology Advantage Non-Small Cell Lung Cancer Alexandria, VA
05/18, 06/18, 07/18, 08/18	Educator	Palliative Care and Symptom Management	American Society of Clinical Oncology Advantage Pancreatic Cancer and Multiple Myeloma Alexandria, VA
04/18, 04/19, 04/20, 04/21	Educator and Panelist	1. Feeling Blah – Management of Anorexia Cachexia, Fatigue, and Insomnia 2. Ask the Symptom Experts	Harvard Medical School Center for Palliative Care Palliative Care and Education Practice (PCEP) Cambridge, MA
09/19	Educator	Advanced Pain Pharmacotherapies	Harvard Medical School Center for Palliative Care Practical Aspects of Palliative Care (PAPC) Cambridge, MA
06/22	Educator and Panelist	1. Hepatocellular Carcinoma: Managing Symptoms Throughout the Disease Trajectory 2. Tumor board discussant	American Society of Clinical Oncology Advantage Non-Small Cell Lung Cancer Alexandria, VA (Teleconference during the COVID pandemic)

<u>Regional/Local</u>

Date	*Role*	*Topics*	*Program*

05/22	Expert Discussant	Cancer Cachexia	University of California San Diego Moores Cancer Center Hematology/Oncology Fellows' Weekly Core Lecture Series San Diego, CA
07/23, 07/24	Expert Discussant	Supportive Oncology	Oregon Health and Science University Knight Cancer Institute Hematology/Oncology Fellows' Weekly Core Lecture Series Portland, OR
08/24	Speaker	Immunotherapy toxicity	Oregon Health and Science University Hospice and Palliative Medicine Fellows' Weekly Core Lecture Series Portland, OR
10/24	Speaker	Cancer Cachexia	Oregon Health and Science University Hospice and Palliative Medicine Fellows' Weekly Core Lecture Series Portland, OR
05/25	Speaker	Immune Checkpoint Inhibitor Toxicities: Essential Insights for the Practicing Clinician	Providence St. Vincent Medical Center Internal Medicine Grand Rounds Portland, OR

Mentoring and Coaching

Mentees					
Total (n)	28				
Career stage		*Medical Specialty*	1	*Non-Medical Specialty*	1
Pre-doctoral	7	Internal Medicine	3	Social Work	1
Trainee	15	Hospice and Palliative Medicine	2	Psychology	1
Doctoral	1	Hematology/Oncology	1	Chaplain	2
Post-doctoral	1	Radiation Oncology	1	Public Health	1
Mid-career	5	Pharmacy	1	Biostatistics	1
Mentee Publications					
Total (n)	31	Mentee First Author (n)	16		
Mentee Grants Awards					
Annual Meeting Travel Award (n)	3	*Career Development Award (n)*	*3*	*Foundation Pilot Awards (n)*	*2*